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Abstract
Essential genes (EGs) play central roles in fundamental cellular processes and are required for the survival of
an organism. EGs are enriched for human disease genes and are under strong purifying selection. This
intolerance to deleterious mutations, commonly observed haploinsufficiency and the importance of EGs in
pre- and postnatal development suggests a possible cumulative effect of deleterious variants in EGs on
complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a heterogeneous, highly
heritable neurodevelopmental syndrome characterized by impaired social interaction, communication and
repetitive behavior. More and more genetic evidence points to a polygenic model of ASD and it is estimated
that hundreds of genes contribute to ASD. The central question addressed in this dissertation is whether genes
with a strong effect on survival and fitness (i.e. EGs) play a specific role in ASD risk. I compiled a
comprehensive catalog of 3,915 mammalian EGs by combining human orthologs of lethal genes in knockout
mice and genes responsible for cell-based essentiality. With an updated set of EGs, I characterized the genetic
and functional properties of EGs and demonstrated the association between EGs and human diseases. Next I
provided evidence for a stronger contribution of EGs to ASD risk, compared to non-essential genes (NEGs).
By examining the exonic de novo and inherited variants from 1,781 ASD quartet families, I demonstrated a
significantly higher burden of damaging mutations in EGs in ASD probands compared to their non-ASD
siblings. Analysis of EGs in the developing brain identified clusters of co-expressed EGs implicated in ASD,
among which I proposed a priority list of 29 EGs with potential ASD risk as targets for future functional and
behavioral studies. Finally, I developed the essentiality burden score (EBS), which captures the burden of rare
mutations in EGs as a novel polygenic predictor of individual ASD risk and a useful addition to the current
tools for understanding the polygenic architecture of ASD. Overall, I show that large-scale studies of gene
function in model organisms and human cell lines provide a powerful approach for prioritization of genes and
pathogenic variants identified by sequencing studies of complex human disease.
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ABSTRACT 
ESSENTIAL GENES AND THEIR ROLE IN AUTISM SPECTRUM DISORDER 
Xiao Ji 
Maja Bucan 
Essential genes (EGs) play central roles in fundamental cellular processes and are 
required for the survival of an organism. EGs are enriched for human disease genes and 
are under strong purifying selection. This intolerance to deleterious mutations, commonly 
observed haploinsufficiency and the importance of EGs in pre- and postnatal 
development suggests a possible cumulative effect of deleterious variants in EGs on 
complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a 
heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired 
social interaction, communication and repetitive behavior. More and more genetic 
evidence points to a polygenic model of ASD and it is estimated that hundreds of genes 
contribute to ASD. The central question addressed in this dissertation is whether genes 
with a strong effect on survival and fitness (i.e. EGs) play a specific role in ASD risk. I 
compiled a comprehensive catalog of 3,915 mammalian EGs by combining human 
orthologs of lethal genes in knockout mice and genes responsible for cell-based 
essentiality. With an updated set of EGs, I characterized the genetic and functional 
properties of EGs and demonstrated the association between EGs and human diseases. 
Next I provided evidence for a stronger contribution of EGs to ASD risk, compared to 
non-essential genes (NEGs). By examining the exonic de novo and inherited variants 
from 1,781 ASD quartet families, I demonstrated a significantly higher burden of 
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damaging mutations in EGs in ASD probands compared to their non-ASD siblings. 
Analysis of EGs in the developing brain identified clusters of co-expressed EGs 
implicated in ASD, among which I proposed a priority list of 29 EGs with potential ASD 
risk as targets for future functional and behavioral studies. Finally, I developed the 
essentiality burden score (EBS), which captures the burden of rare mutations in EGs as a 
novel polygenic predictor of individual ASD risk and a useful addition to the current 
tools for understanding the polygenic architecture of ASD. Overall, I show that large-
scale studies of gene function in model organisms and human cell lines provide a 
powerful approach for prioritization of genes and pathogenic variants identified by 
sequencing studies of complex human disease.  
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CHAPTER 1: Introduction 
One of the central goals of human genetics studies is to understand the genetic 
contribution to human diseases. This knowledge is of great value in combating disease 
and promoting human health. The genes responsible for a wide range of Mendelian 
disorders, such as sickle cell anemia, cystic fibrosis, and Huntington’s disease, have been 
well understood by the genetics community (Stenson et al., 2014). However, it has been a 
challenge to identify risk genes and variants underlying a majority of common complex 
diseases including cardiovascular diseases, cancer, diabetes and psychiatric disorders, 
where complicated interactions of multiple genes and environmental factors are involved 
in their etiology (Risch, 2000; Wray et al., 2014). There has been an ongoing debate in 
the field of genetics over how genetic variations contribute to the risk of common 
complex diseases. The ‘common disease-common variant’ hypothesis predicts that 
common genetic variants with low penetrance are the major contributors of individual 
susceptibility to complex diseases. In contrast, the ‘common disease-rare variant’ 
hypothesis argues that the risk of complex disease is mainly due to rare variants that are 
more specific to individuals with relatively high penetrance. Both hypotheses have their 
place in current research and are supported by substantial evidence, therefore it is 
important to evaluate the contribution of both common and rare variants to the risk of 
complex diseases (Gibson, 2012; Schork et al., 2009). The key to identifying genetic 
variants contributing to complex diseases is to pinpoint risk genes and variants from a 
huge number of those that are biologically insignificant or irrelevant for that disease. 
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Important advances in the study of complex disease were the development of 
technologies that enable systematic interrogation of many genetic variants in large 
cohorts of patients. Single nucleotide polymorphism (SNP) array-based genome-wide 
association studies (GWAS) represent a powerful tool for uncovering the common 
genetic variants that underlie risk of complex diseases. Furthermore, next generation 
sequencing technologies enable the investigation of the role of low-frequency or rare 
variants in complex diseases, which may explain additional disease risk or trait 
variability. However, despite the genetic associations discovered though the studies of 
both common and rare variants, a full understanding of the genetic architecture of most 
complex disorders has yet to be achieved. 
One of the substantial challenges for current sequencing-based association studies of 
complex diseases comes from the limitation of the classical single variant-based 
association test, where limited sample sizes, modest effect sizes of variants and the 
multiple testing burden restricts its statistical power (Lee et al., 2014). As an alternative 
approach, aggregation tests that evaluate the cumulative effect of multiple variants in a 
gene or region can increase statistical power when a group of variants are associated with 
a disease or trait of interest (Lee et al., 2014; Li and Leal, 2008; Madsen and Browning, 
2009; Wu et al., 2011). Following the concept of gene- or region-level aggregation tests, 
a top-down strategy starts from identifying a large set of genes with key characteristics 
that are known to play a role in studied diseases. Groups of variants in these candidate 
gene sets are then jointly tested in order to increase statistical power. This strategy was 
applied by a number of recent genetic studies of schizophrenia. For example, Purcell et 
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al. performed a polygenic burden test of rare disruptive mutations in schizophrenia 
candidate gene sets (including synaptic genes, voltage-gated calcium channel genes and 
targets of the fragile X mental retardation protein) using exome sequences of ~2,500  
schizophrenia cases and ~2,500 controls (Purcell et al., 2014). In addition, copy number 
variant (CNV) burden within gene sets involved in neurodevelopmental or neurological 
function was assessed in a schizophrenia cohort of ~20,000 cases and ~20,000 controls 
(Cnv et al., 2017). These studies provided a proof-of-principle that the candidate gene set 
approach which evaluates the aggregational effect of multiple variants can facilitate the 
discovery of risk alleles in neuropsychiatric diseases. 
Of all of the genes in the genome, there is a subset of essential genes (EGs) that play 
central functional roles and are required for the survival of an organism. The 
identification and characterization of the core set of genes that are necessary for basic 
developmental functions, i.e. the “essentialome”, is an important biological question by 
itself, as it provides insights into the molecular basis for key biological processes in 
multiple organisms including human (Zhan and Boutros, 2016). In S. cerevisiae (budding 
yeast), ~ 20% of ~ 6,000 genes are necessary for viability and proliferation in rich 
medium (Giaever et al., 2002; Winzeler et al., 1999). However, in addition to the core set 
of EGs that result in lethal phenotype upon loss, there are other genes that are 
conditionally essential. These genes have been extensively studied in S. cerevisiae. It has 
been shown that yeast mutants with one of these genes deleted are sensitive to additional 
perturbations such as stress conditions (Giaever et al., 2002), chemicals (Costanzo et al., 
2010; Hillenmeyer et al., 2008) and knock out of a second gene (i.e. synthetic lethality) 
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(Costanzo et al., 2010; Nijman, 2011). Therefore, deciding whether these genes also 
count as essential is a matter for discussion. In multicellular organisms, many EGs are 
housekeeping genes that are required for maintaining basal cellular functions and tend to 
be ubiquitously expressed at constant levels in all cell types (Eisenberg and Levanon, 
2013). However, some other EGs in multicellular organisms can be restricted to the 
function of specific tissues or certain developmental stages (Zhan and Boutros, 2016). 
For example, mice with targeted disruption of Fatp4 gene that encodes a fatty acid 
transport protein died shortly after birth because of a skin defect (Herrmann et al., 2003). 
The Fatp4 knockout mice could be rescued by introducing transgenic expression of 
Fatp4 in skin cells (Shim et al., 2009). In contrast, adipocyte-specific inactivation of 
Fatp4 did not result in severe phenotypes in mice (Lenz et al., 2011), showing that Fatp4 
is likely to be required for the proper function of a single tissue, whereas it is essential for 
the viability of the whole organism. In the scope of this dissertation, I defined an EG as a 
gene that causes lethality of a multicellular organism when fully knocked-out, whether 
the gene is essential in all tissues or not. 
Historically, forward genetics strategies based on chemically induced, radiation-induced 
or insertional mutagenesis had been extensively applied to investigate the link between 
genotypes and phenotypes (Zhan and Boutros, 2016). In C. elegans, Clark et al. and 
Johnsen & Baillie independently identified hundreds of lethal mutations in specific 
chromosomal regions using ethyl methanesulfonate (EMS) mutagenesis. They estimated 
that the total number of EGs in C. elegans is at least 2,850~3,500, which accounts for 
15~18% of all protein coding genes in the C. elegans genome (Clark et al., 1988; Johnsen 
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and Baillie, 1991). In D. melanogaster, P-transposable element has been widely used to 
disrupt Drosophila genes. For instance, the Berkeley Drosophila Genome Project 
generated mutant lines for 40% of Drosophila genes and observed that 8~16% of genes 
led to lethal phenotypes when disrupted (Bellen et al., 2004).  
Built on the foundation of the completed genome sequences of many model organisms, 
reverse genetics approaches enabled the exploration of gene essentiality on a genome-
wide scale. RNA interference (RNAi) based gene silencing has been proved to be a 
successful strategy in discovering EGs. Kamath et al. used RNAi to inhibit the function 
of ~16,700 genes in C. elegans, and identified mutant phenotypes of 1,722 genes. 68% of 
these genes (n=1,170) exhibited nonviable RNAi phenotypes (Kamath et al., 2003). 
Boutros et al. performed genome-wide RNAi analysis of the growth and viability in 
Drosophila cells and identified 438 EGs, among which 80% lacked known mutant alleles 
in Drosophila (Boutros et al., 2004). Dietzl et al. generated a genome-wide library of 
22,270 RNAi transgenic Drosophila lines that covered 88% of the predicted protein-
coding genes in Drosophila, among which 17.5% of transgenic lines exhibited lethal 
phenotypes (Dietzl et al., 2007). While these studies generated sizable catalogs of EGs in 
studied organisms, the percentages of EGs discovered varied in these studies due to 
common limitations of RNAi screens such as variability and incompleteness of 
knockdowns as well as potential nonspecificity of RNAi targets (Boutros and Ahringer, 
2008). Regardless, these studies do not necessarily contradict the estimation from Miklos 
& Rubin that around one third of genes are essential for viability in these model 
organisms (Miklos and Rubin, 1996). 
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Identification of EGs in the mouse is of particular interest due to the evolutionary 
closeness between mouse and human, as well as the great potential of mouse models in 
translational research. Over decades, the genetics community collected a substantial 
amount of phenotypic data in knockout mouse strains generated by both forward and 
reserve genetics approaches such as ethyl-nitrosourea (ENU) mutagenesis, transposon 
mutagenesis, gene trapping and gene targeting in mouse embryonic stem cells (Eppig et 
al., 2005). Based on reported homozygous embryonic/perinatal lethal mouse mutants, it 
was estimated that ~30% of mouse genes are essential for mouse viability (Dickinson et 
al., 2016; White et al., 2013). Due to the extensive similarity between the genomes of 
mouse and human, human EGs can be inferred from the human orthologs of prenatal or 
preweaning lethal genes in the mouse (Dickerson et al., 2011; Feldman et al., 2008; 
Georgi et al., 2013; Goh et al., 2007; Park et al., 2008). We are particularly interested in 
the potential connection between EGs and human disease. Earlier studies of human 
orthologs of EGs in the mouse proposed that the majority of human disease genes are 
non-essential, because mutations in EGs prevent viability and thus do not contribute to 
human disease (Domazet-Loso and Tautz, 2008; Feldman et al., 2008; Goh et al., 2007; 
Park et al., 2008) . However, the role of EGs in human disease could be underestimated, 
since some of these studies also presented contrasting evidence showing that human 
disease genes can also display some characteristics of EGs, such as high connectivity in 
gene networks (Goh et al., 2007) and an early evolutionary emergence (Domazet-Loso 
and Tautz, 2008). More recent studies on human orthologs of EGs in the mouse began to 
redefine the role of EGs in human disease. With an analysis of the overlap between 1,299 
EGs and known human disease genes, Dickerson et al. pointed out that EGs actually 
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comprised a major portion of disease genes (Dickerson et al., 2011). Georgi et al. 
reinforced this notion by showing an enrichment of disease genes among an updated list 
of 2,472 human orthologs of EGs in the mouse (Georgi et al., 2013). 
To better understand to role of EGs in human disease, it is helpful to clarify the 
difference in mutational spectrums of EGs and non-essential genes (NEGs). In a disease-
associated NEG, we may observe disease phenotypes when homozygous loss-of-function 
mutations or compound heterozygosity of null alleles occur in an individual. However in 
an EG, we won’t observe homozygous loss-of-function mutations in living individuals 
because they cause lethality. Instead, EGs could contribute to human disease through 
milder alleles other than functionally null alleles (Figure 1.1). It has been shown that EGs 
exhibit a reduced number of exonic missense (Georgi et al., 2013; Petrovski et al., 2013) 
and loss-of-function (Lek et al., 2016) variants in general population, as well as a shift in 
allele frequency towards rare alleles (Georgi et al., 2013). Moreover, previous studies 
showed evidence that EGs are prone to exhibiting haploinsufficiency (Deutschbauer et 
al., 2005; Georgi et al., 2013), which suggests that heterozygous alleles in EGs are more 
likely to be deleterious and pathogenic. These observations support the functional 
importance of EGs in humans and implicate that EGs are more likely to have functional 
consequences when mutated.  
In this dissertation, I investigated the connection between EGs and human diseases, with 
a focus on a neurodevelopmental disease - autism spectrum disorder (ASD). ASD is a 
neurodevelopmental disorder characterized by repetitive behavior and impairments in 
social interaction, communication and language (2013). The signs of autism begin to 
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appear over the first year of life (Ozonoff et al., 2008). According to the latest survey 
from the Centers for Disease Control and Prevention, the prevalence of ASD is 1 in 68, 
and males are 4.5 times more likely to develop ASD compared to females (Christensen, 
2016). There is general agreement across family and twin studies that the heritability of 
ASD is between ~60% to ~90% (Bailey et al., 1995; Folstein and Rutter, 1977; 
Hallmayer et al., 2011; Lichtenstein et al., 2010; Ronald and Hoekstra, 2011; Sandin et 
al., 2014). The genetic causes of ASD are highly heterogeneous among patients, and 
identified ASD linked mutations accounting for more than 1% of ASD cases are very rare 
(Jeste and Geschwind, 2014; State and Sestan, 2012). It has been demonstrated that 
common variants carry a substantial ASD risk (Anney et al., 2012; Gauglerl et al., 2014; 
Klei et al., 2012; Wang et al., 2009), which supports the ‘common disease-common 
variant’ hypothesis in ASD. Based on this hypothesis, a number of ASD risk loci were 
discovered through genetic linkage analysis (Szatmari et al., 2007; Weiss et al., 2009) 
and GWAS (Anney et al., 2010; Ma et al., 2009; Wang et al., 2009). However, it is 
difficult to identify and replicate the ASD-linked common variants by these traditional 
genetic tests due to their small effect sizes and currently limited sample size (~5,000 
ASD cases). Based on the “common disease-rare variant” hypothesis, many ASD studies 
that focused on protein-disrupting, rare de novo variants in affected children have 
successfully implicated hundreds of single nucleotide variants (SNVs) and copy number 
variants (CNVs) as potential ASD risk factors (Bucan et al., 2009; De Rubeis et al., 2014; 
Gilman et al., 2011; Glessner et al., 2009; Gratten et al., 2013; Griswold et al., 2012; 
Iossifov et al., 2014; Iossifov et al., 2012; Itsara et al., 2010; Levy et al., 2011; Marshall 
et al., 2008; Neale et al., 2012; O'Roak et al., 2012a; O'Roak et al., 2012b; Pinto et al., 
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2010a; Sanders et al., 2011; Sanders et al., 2012; Sebat et al., 2007; Szatmari et al., 
2007). However, a large proportion of ASD heritability remains unexplained and the 
genetic mechanisms involved in ASD are still not fully understood. As a way to explain 
the complexity of the genetic architecture of ASD, more and more genetic evidence 
points to a polygenic model of ASD (de la Torre-Ubieta et al., 2016), i.e. at least 
hundreds of genes and a large number of common variants with modest effect, and rare or 
de novo variants with strong effect, contributing to ASD risk collaboratively.   
The early on-set of ASD suggests a prenatal or early postnatal origin. Multiple lines of 
evidence implicated that impairments of early brain development were involved in the 
pathogenesis of ASD (Parikshak et al., 2013; Stoner et al., 2014; Willsey et al., 2013a). 
For instance, Parikshak et al. found that ASD genes from multiple sources converged on 
pathways implicated in prenatal and early post natal synaptic development (Parikshak et 
al., 2013). Willsey et al. reported convergence of ASD genes on midfetal deep cortical 
projection neurons (Willsey et al., 2013a). Stoner et al. observed disorganization of 
neurons in prefrontal and temporal cortical tissues in 10 of 11 autistic children and 
suggested that such abnormality emerged at prenatal developmental stages (Stoner et al., 
2014). Therefore, EGs as a group of genes that are required for normal pre- and postnatal 
development are prime candidates for the analysis of the polygenic architectures of ASD.  
The objective of this dissertation is to systematically investigate the potential link 
between EGs and ASD, which was proposed by Georgi et al., who observed that genes 
with de novo events in ASD patients are enriched for EGs (Georgi et al., 2013). 
Furthermore, the two hit model of neuropsychiatric disorders was initially proposed by 
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Girirajan & Eichler to explain the phenotypic variability among patients. This model 
suggests that in a network of genes in a pathway associated with neuropsychiatric 
disorders, a single hit initially disrupts the pathway and results in a milder phenotype, and 
a second hit further damages the pathway to generate a much more severe phenotype 
(Girirajan and Eichler, 2010). Therefore, in neurodevelopmental disorders where 
individual candidate genes cannot fully explain their genetic basis, it is possible that 
multiple deleterious variants in EGs constitute a genetic background that influences an 
individual’s disease risk. I hypothesized that a cumulative effect of a range of alleles in 
EGs may contribute to developmental or behavior anomalies such as ASD. In this thesis, 
my aims are to address these challenges as follows.  
In Chapter 2, I identified and compiled the most comprehensive set of EGs to-date by 
combining data from cell-based assays in human cell lines and systematically phenotyped 
knock-out mice. I characterized the genetic and functional properties of EGs and 
demonstrated the association between EGs and human disease. 
In Chapter 3, I provided compelling evidence for a significant contribution of EGs to 
ASD risk compared to NEGs by showing a higher burden of damaging mutations in EGs 
in ASD probands and enrichment of EGs among currently known ASD risk genes. 
Moreover, I identified clusters of co-expressed EGs implicated in ASD through the 
analysis of EGs in the developing brain.  
In Chapter 4, I developed the essentiality burden score (EBS), based on exonic rare 
variants in EGs, as a novel predictor to ASD risk. I compared EBS, polygenic risk score 
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(PRS), and rare CNV burden to evaluate their performance in predicting ASD disease 
risk. Furthermore, I investigated the interplay between EBS and rare variants in a high-
penetrant ASD risk gene, NRXN1. 
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Figures 
 
 
 
 
 
 
 
Figure 1.1 Distinct mutational spectrums of variants in essential and non-essential 
genes. Loss-of-function variants (in red) in both alleles (circles) of essential genes (A) 
lead to lethality or miscarriages when homozygous (depicted as embryo) and are likely to 
lead to a disease phenotype (shaded gray) when they are heterozygous. Loss-of-function 
variants in many non-essential genes (B) produce a disease phenotype when homozygous 
and no disease phenotype when heterozygous (shaded white). Hypomorph alleles 
(yellow) in essential genes may produce a disease phenotype when homozygous or may 
lead to lethality when combined with another hypomorph or loss-of-function allele in the 
same gene.  Benign alleles are depicted with different colored circles. 
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CHAPTER 2: Characterization of essential genes 
Introduction 
Research of gene essentiality has potential implications for the genetic basis of human 
disease. However, it is difficult to identify EGs directly from human studies because null 
mutations in EGs are missing in living individuals. A number of EGs were implicated 
through case studies of families with mutations in genes linked to miscarriages or lethal 
birth defects (Malfatti et al., 2014; Michalk et al., 2008; Stangenberg et al., 1992). 
Because of low sample sizes available for these case studies, the number of human EGs 
discovered through this method is limited. For example, Stangenberg et al. reported a 
patient with recurrent miscarriages who delivered a hydropic stillborn infant with β-
Glucuronidase (GUSB) deficiency (Stangenberg et al., 1992). Michalk et al. found that 
one fetus had homozygous loss-of-function mutations in CHRNA1 which could disable 
the function of acetylcholine receptor and lead to intrauterine death (Michalk et al., 
2008). Moreover, Malfatti et al. reported five NEB-mutated infants who presented severe 
congenital myopathy leading to death in the first day after birth (Malfatti et al., 2014). 
Interestingly, the mouse orthologs of GUSB, NEB and CHRNA1 also cause pre- or 
perinatal lethality when knocked out in mouse, according to phenotypic data of knockout 
mice from Mouse Genome Informatics (MGI) (Eppig et al., 2005).  
In order to systematically investigate gene essentiality in human, EGs are often inferred 
from the human orthologs of prenatal or preweaning lethal genes in the mouse based on 
the extensive similarity between the genomes of mouse and human (Dickerson et al., 
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2011; Feldman et al., 2008; Georgi et al., 2013; Goh et al., 2007; Park et al., 2008). For 
example, using phenotypic data of knockout mice from MGI (Eppig et al., 2005), 
Dickerson et al. and Georgi et al. identified 1,299 and 2,472 human orthologs of lethal 
genes in the mouse, respectively (Dickerson et al., 2011; Georgi et al., 2013). Based on 
targeted mutant embryonic stem cells generated by the International Knock-out Mouse 
Consortium (IKMC) (Skarnes et al., 2011), the International Mouse Phenotyping 
Consortium (IMPC) generated and phenotyped 1,751 new knockout mouse lines on a 
uniform C57BL/6N background, among which 410 knockout lines displayed preweaning 
lethality (Dickinson et al., 2016). This study is consistent with previous observation that 
30% (or ∼6,000) of protein-coding genes are essential for pre- and postnatal survival in 
the mouse (Dickinson et al., 2016; White et al., 2013). Remarkably, the IMPC also 
identified 198 subviable knockout lines, which demonstrated that some genes may exhibit 
incomplete penetrance and variable expressivity even on a defined genetic background 
(Dickinson et al., 2016).  
Human cell line based assays are complementary approaches to identify human EGs. 
RNA interference (RNAi) libraries targeting the human genome enabled earlier studies to 
identify cell EGs (Harborth et al., 2001; Luo et al., 2008; Silva et al., 2008). For example, 
Luo et al. performed RNAi screens in 12 cancer cell lines and identified 268 common 
EGs among the 12 cell lines (Luo et al., 2008). Recently, three genome-wide scale 
screens based on CRISPR/Cas9 gene editing system have been performed to assess the 
effect of single-gene disruption on survival of haploid human cancer cell lines (Blomen et 
al., 2015; Hart et al., 2015; Wang et al., 2015). These studies systematically uncovered 
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genes responsible for cell-based essentiality in human cell lines in a genome-wide scale. 
Wang et al. presented 1,878 cell essential genes in the near-haploid chronic myeloid 
leukemia cell line KBM7 (Wang et al., 2015). Blomen et al. identified 1,734 genes that 
were required for optimal growth for both KBM7 and HAP1 cell lines (Blomen et al., 
2015). Hart et al. observed 1,580 genes whose perturbation decreased cell growth and 
proliferation in more than three studied cell lines (Hart et al., 2015). Although the core 
EGs discovered in these studies overlap greatly, the number of EGs identified in each 
study varies because different cell lines were selected and different thresholds were used 
for determining cell viability. 
Previous studies have reported some key characteristics of EGs. Firstly, EGs tend to 
encode hub proteins that are most highly connected in biological networks (Goh et al., 
2007; Jeong et al., 2001), showing the functional importance of EGs. Secondly, EG are 
often highly conserved across species. The conservation of EGs is supported by several 
comparative genomic studies in bacterial genomes (Bergmiller et al., 2012; Gerdes et al., 
2003; Jordan et al., 2002; Luo et al., 2015) and Georgi et al., who found that EGs exhibit 
increased conservation across rodent and primate lineages compared to the rest of genes 
in the genome (Georgi et al., 2013). Thirdly, EGs are more likely to be under purifying 
selection, which is supported by observations that EGs were intolerant to exonic missense 
(Georgi et al., 2013; Petrovski et al., 2013) and loss-of-function (Lek et al., 2016) 
variants in general populations. Lastly, EGs are prone to exhibiting haploinsufficiency, as 
is suggested by both Deutschbauer et al. and Georgi et al. who found enrichment of EGs 
among haploinsufficient genes (Deutschbauer et al., 2005; Georgi et al., 2013).   
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In this chapter, I set out to compile a comprehensive list of EGs in human by combining 
the legacy mouse phenotyping data from MGI (Eppig et al., 2005), the newly uncovered 
lethal and subviable mouse genes from IMPC and human cell EGs from recent 
CRISPR/Cas9-based studies. With an updated set of EGs, I characterized the genetic and 
functional properties of EGs and confirmed the association between EGs and human 
disease. 
Results 
Identification of a comprehensive list of human orthologs of essential genes in the 
mouse 
To identify a comprehensive list of human orthologs of EGs in the mouse, I established 
orthology between genes in mice and humans (Eppig et al., 2005), and used the Human 
Genome Mutation Database (HGMD) (Stenson et al., 2014) to annotate human disease 
associations. I next combined the published data from the MGI database (MP terms listed 
in Table 2.1) and 608 genes identified in the IMPC effort as causing lethality and 
subviability to compile an updated list of 3,326 EGs, along with 4,919 nonessential genes 
(NEGs).  
The IMPC effort expanded a phenotypic spectrum for over 300 genes associated with 
known Mendelian diseases. From 194 subviable genes with identified human orthologs, 
57 were associated with human disease, of which 34 were previously unreported for their 
subviable phenotypes (Supplementary Data 2.1; new reports indicated by ‘N’ in column 
J). For example, SET binding protein 1 (SETBP1) has been reported as frequently 
17 
 
mutated in several types of chronic leukaemia and in Schnizel-Giedion syndrome, a 
congenital disease characterized by a high prevalence of tumors, severe mid-face 
hypoplasia, heart defects and skeletal anomalies (Piazza et al., 2013; Schinzel and 
Giedion, 1978). Among 399 lethal genes, 126 human orthologs have been associated with 
human diseases, including 52 disease genes for which the IMPC effort provides the first 
report of their null phenotype in the mouse (Supplementary Data 2.2). The human 
orthologs of these novel lethal genes have been linked to metabolic and storage 
syndromes (ADSL, DHFR, GYG1, PC), mitochondrial complex deficiencies (ATP5E, 
NDUFS1, NUBPL, SDHA, SLC25A3, UQCRB), or syndromes caused by disruption of 
basic processes such as replication or translation initiation (EIF2B3, EIF2B4, ORC1). 
The severity of clinical manifestation of these human syndromes ranges from neonatal 
lethality (BBS10, SLC25A3) matching the observed phenotype in the mouse, to 
neurological disorders and intellectual disability (COQ6, DEPDC5, GOSR2, KDM5C, 
YARS). These differences in clinical manifestation may be due to differences between 
underlying biological processes in the mouse and human.  
Expansion of the essential gene list through genome-wide screens for cell-essential 
genes in human cell lines 
I used data from three recent publications on genome-wide screens for cell-essential 
genes in human cells to address the overlap between essential genes in the human and 
mouse genome (Blomen et al., 2015; Hart et al., 2015; Wang et al., 2015). I selected core 
essential human genes from each study and compared these to the human orthologs of 
mouse essential genes on the consensus list of curated IMPC-MGI genes (see Materials 
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and Methods). I found that approximately 35% of core essential genes in each study were 
associated with lethality or subviability in the mouse, and that mouse null-phenotypes for 
61–62% of genes were currently unknown (Figure 2.1). Of the 19 human essential genes 
common to all three studies that were nonessential in the mouse, only three (Rbmx, Dkc1, 
and Sod1) could reliably be confirmed as a targeted knockout of a nonessential gene, 
highlighting the remarkable concordance between mouse and human in their core 
essential genes. 
From these cell-based studies of EGs, I identified an overlapping core set of genes that 
were essential in the majority of cell lines tested (n = 956), but not necessarily all cell 
lines tested. To identify the most comprehensive set of EGs in mammals, I combined the 
set of human orthologs of EGs in the mouse (n =3,326) with a set of human “core EGs” 
(n = 956) that were found to be essential in cell-based assays (Blomen et al., 2015; Hart 
et al., 2015; Wang et al., 2015). Based on the significant overlap between tested mouse 
and human EGs, I expanded our original set of 3,326 EGs with the addition of 
nonoverlapping 589 EGs identified only in human cell lines for a total of 3,915 EGs 
(Materials and Methods, Supplementary data 2.3). In my subsequent analyses, I analyzed 
and compared the features of these 3,915 EGs with 4,919 human orthologs of genes with 
reported nonlethal phenotypes in the mouse [nonessential genes (NEGs)].  
Enrichment of human disease genes and genes neighboring GWAS hits among 
essential genes 
It has been shown that genes causing lethality in mice are enriched in human disease 
genes (Dickerson et al., 2011; Georgi et al., 2013). With these updated EG lists, I report 
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an even stronger enrichment of essential genes relative to nonessential for human disease 
genes catalogued in the HGMD (odds ratio = 2.00, P = 6.83 × 10−39, Figure 2.2A). 
Consistent with this enrichment, of the 3,302 protein-coding HGMD disease genes, 2,434 
have a reported phenotype and more than half (1,253) are essential in mice (Figure 2.2B; 
Supplementary Data 2.3). Furthermore, I found an enrichment of EGs in comparison to 
nonessential genes (odds ratio = 1.16, P value = 0.0015) among 6,384 genes 
encompassing or neighboring the disease- and trait-associated variants in the NHGRI-
EBI catalogue of published genome-wide association studies (‘GWAS hits’) (Welter et 
al., 2014) (Figure 2.3). 
Essential genes’ intolerance to deleterious mutations 
With the updated catalog of mouse 3,326 EGs and 4,919 NEGs, I compared the 
mutability of their human orthologs in exome sequences of 60,706 subjects in the Exome 
Aggregation Consortium data (ExAC, http://exac.broadinstitute.org) (Lek et al., 2016). 
The ExAC data were used to generate intolerance scores for all protein-coding genes by 
two complementary methods: a) the residual variation intolerance score (RVIS), which is 
based on intolerance to common missense and truncating single nucleotide variation 
(http://genic-intolerance.org/) (Petrovski et al., 2013); and b) the estimation of probability 
of being loss-of-function intolerant (pLI score) (Lek et al., 2016). Human orthologs of 
EGs are more intolerant to variation (low RVIS and high pLI scores) than orthologs of 
NEGs and all genes in the human genome (P value < 2.2 × 10−16 for lower percentiles in 
essential genes using the two scoring systems, Figure 2.4A, B). Moreover, the IMPC 
effort identified a set of 22 human orthologs of EGs that were not previously associated 
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with human disease (Figure 2.5, Table 2.2), but based on their intolerance to functional 
variation and lethality of their null alleles in the mouse, they represent strong candidates 
for undiagnosed human diseases. 
Chromosomal distribution of essential genes 
EGs are distributed throughout the human genome, with the exception of the Y 
chromosome (Figure 2.6). I identified 3 chromosomal regions, 17q21, 11q13 and 16q22, 
with significant enrichment of EGs (FDR<0.05; one-sided Fisher’s exact test) 
(Supplementary data 2.4). 17q21 contains 64 EGs which collectively cover 14.0% (1.69 
Mb) of the total length of the region. 11q13 contains 63 EGs which collectively cover 
15.5% (2.13 Mb) of the total length of the region. 16q22 contains 37 EGs which 
collectively cover 29.3% (2.17 Mb) of the total length of the region. I further annotated 
these three chromosomal regions with associated human diseases from OMIM (Hamosh 
et al., 2005) and identified 91 human disease loci (including frontotemporal dementia, 
progressive myoclonic epilepsy-6 and mental retardation) associated with 17q21, 59 
disease loci associated with 11q13, as well as 30 disease loci associated with 16q22 
(Supplementary data 2.4). Interestingly, 17q21 has been shown by replicated genome-
wide linkage studies (Cantor et al., 2005; Yonan et al., 2003) to harbor susceptibility to 
autism spectrum disorder (ASD). In the mouse genome, I identified 2qB as the only 
chromosomal region with significant enrichment of EGs in the mouse (44 EGs vs. 21 
NEGs; P value =0.048; One-sided Fisher’s exact test after Bonferroni correction) (Figure 
2.7, Supplementary data 2.5).  
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Disease categories associated with essential genes 
To systematically evaluate the relevance of EGs in diseases categorized by affected 
tissues and age of onset, I obtained lists of human disease genes annotated by the Human 
Phenotype Ontology (Kohler et al., 2017). First, I tested for enrichment of 3,915 EGs vs. 
4,919 NEGs among 24 genes sets associated with abnormality of different organs or 
systems. Except for one disease category (“Abnormality of the thoracic cavity”), all of 
the gene sets associated with the rest of the 23 disease categories were significantly 
enriched for EGs (Table 2.3), which suggests that disturbance of EGs may contribute to a 
wide variety of diseases affecting different organs or systems. When genes were 
categorized by the age of onset of their associated diseases, I observed that EGs are 
significantly enriched among disease genes annotated as “congenital onset” (at birth) 
(Odds ratio=3.84, P value=6.59×10-13; Two sided Fisher’s exact test), “neonatal onset” 
(within 28 days) (Odds ratio=3.15, P value=0.015) and “infantile onset” (between 28 
days and 1 year) (Odds ratio=2.44, P value=8.29×10-11), but not among genes annotated 
as “childhood onset” (between 1 year and 5 years) (Odds ratio=1.01, P value=1), 
“juvenile onset” (between 5 years and 15 years) (Odds ratio=1.16, P value=0.56) or 
“adult onset” (16 years or later) (Odds ratio=1.43, P value=0.083) (Figure 2.8). These 
results suggest that EGs may play a distinct role in early on-set diseases.  
Expression patterns of essential genes across tissues 
To evaluate the tissue specificity and ubiquitousness of EG expression, we analyzed the 
expression patterns of EGs and NEGs over multiple human tissues using transcriptomic 
data from GTEx (The GTEx Consortium, 2015). Compared to NEGs, a higher proportion 
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of EGs are ubiquitously expressed and a lower proportion of EGs are specifically 
expressed in certain tissues (Figure 2.9). Among 6,455 ubiquitously expressed genes 
(entropy score>=5.5), there were 1,477 EGs and 941 NEGs, representing a significant 
enrichment of EGs (Two-sided Fisher’s exact test: p-value=2.10×10-134, Odds ratio=3.42) 
(Supplementary data 2.3). Among 1,680 genes specifically expressed in certain tissues 
(entropy score<=1.0), there were 116 EGs and 415 NEGs, representing a significant 
depletion of EGs (Two-sided Fisher’s exact test: p-value=1.58×10-29, Odds ratio=0.33). 
The top 5 tissue types containing tissue-specifically expressed EGs were testis (with 27 
EGs), liver (with 15 EGs), muscle (with 12 EGs), kidney (with 8 EGs) and brain (with 7 
EGs) (Table 2.4).   
Haploinsufficiency of essential genes 
Homozygous loss-of-function mutations in EGs lead to lethality (or miscarriages in 
humans) and as such, cannot contribute to disease. Although a depletion of loss-of-
function mutations in EGs in humans was reported (Georgi et al., 2013; Petrovski et al., 
2013), heterozygosity for a loss-of-function mutation or other “milder” alleles in EGs 
may contribute to both dominant and recessive diseases. I illustrate this point using a 
catalog of disease-linked genes in Online Mendelian Inheritance in Man (Hamosh et al., 
2005). EGs were enriched relative to NEGs in 1,000 genes underlying dominant diseases 
(odds ratio = 1.95, P value = 3.17 × 10−19; two-sided Fisher’s exact test) and 1,645 genes 
underlying recessive disease (odds ratio = 1.52, P value = 4.94 × 10−11; two-sided 
Fisher’s exact test) (Figure 2.10). A stronger enrichment of EGs among genes underlying 
dominant disease compared to recessive disease implies that dominant negative alleles 
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and haploinsufficiency play an important role. I provide multiple lines of evidence for 
higher probability of haploinsufficiency of EGs (Figure 2.10). First, using the 
systematically rated dosage-sensitive genes from ClinGen (Rehm et al., 2015), I found 
that EGs were significantly enriched compared with NEGs and that the levels of EG 
enrichment positively correlated with levels of evidence supporting dosage sensitivity of 
rated genes (odds ratio = 3.94, P value = 5.07 × 10−20 for “sufficient evidence”; odds ratio 
= 5.26, P value = 7.08 × 10−5 for “some evidence”; odds ratio = 2.52, P value = 0.0106 
for “little evidence”; odds ratio = 1.14, P value = 0.608 for “not dosage sensitive”; two-
sided Fisher’s exact test). Second, as an extension of the earlier findings from the work 
by Georgi et al. (Georgi et al., 2013), I confirmed the enrichment of EG relative to NEG 
for 262 human haploinsufficient genes (Dang et al., 2008) with the updated EG and NEG 
list (183 EGs vs. 62 NEGs; P value = 1.64 × 10−22, odds ratio = 3.84; two-sided Fisher’s 
exact test). Third, EGs are significantly overrepresented among 313 human orthologs of 
mouse genes with heterozygous alleles associated with mutant phenotypes from the MGI 
(Eppig et al., 2005) (odds ratio = 3.43, P value = 2.74 ×10−23; two-sided Fisher’s exact 
test). Fourth, with two genome-wide prediction models of haploinsufficient genes in the 
human genome (Huang et al., 2010; Steinberg et al., 2015), I observed that EGs have 
significantly higher probability of exhibiting haploinsufficiency compared with NEGs (P 
value < 2.2 × 10−16 for both models; two-sided Wilcoxon rank sum test) (Figure 2.11 A 
and B). Based on the findings that EGs linked to Mendelian disease are overwhelmingly 
dosage-sensitive, in Chapter 3 I explored the possibility that a cumulative effect of 
pathogenic variants in multiple EGs may underlie the genetic basis of a complex disease 
with early postnatal onset, such as ASD. 
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Discussion 
I complied the most comprehensive EG set established to date (n=3,915) by combining 
phenotypic data in knockout mice (n=3,326) and data from genomic-scale human cell 
assays (n=956). I confirmed the important role of EGs in human disease by showing that 
EGs comprise a major part of disease genes and that EGs are enriched among genes 
neighboring GWAS hits. While EGs are distributed throughout the genome (with the 
exception of the Y chromosome) and tend to be ubiquitously expressed across different 
tissues, I identified three EG-enriched chromosomal regions, among which 17q21 was 
associated with ASD according to replicated genome-wide linkage studies (Cantor et al., 
2005; Yonan et al., 2003). Finally, with an updated EG set, I confirmed that EGs are 
intolerant to deleterious mutations and are more likely to be haploinsufficient. 
The current catalog of human EGs includes 3,915 genes, which is a substantial increase 
since the publication by Georgi et al. in 2013 (n=2,472) (Georgi et al., 2013). Based on 
studies in the mouse, 30% of genes in a mammalian genome are essential (Dickinson et 
al., 2016; White et al., 2013), meaning that the current catalog includes more than 65% of 
the core set of “the indispensable genome”. With a major portion of EGs identified, the 
general functional and genetic properties of EGs can be credibly characterized, as is 
shown in this chapter. There is still a great amount work to be done to identify the 
complete set of EGs. Systematically generating and phenotyping knockout mice for every 
gene in the mouse genome (~20,000 genes) is a feasible strategy to achieve this goal, 
which has been one of the main objectives of the International Mouse Phenotyping 
Consortium (IMPC) (Dickinson et al., 2016; Koscielny et al., 2014).  
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Recent breakthroughs in human cell line based assays on cell proliferation and survival 
provided an effective alternative way to identify EGs in human (Blomen et al., 2015; Hart 
et al., 2015; Wang et al., 2015). It overcomes some limitations of the knockout mice 
based approach such as biological and genomic differences between mouse and human. 
Indeed, some genes that are essential in one organism may not be essential in other 
organisms, as is suggested by a few comparative genomic studies in bacterial genomes 
(Bergmiller et al., 2012; Gerdes et al., 2003). However, the cell line based approaches 
have their own drawbacks. Firstly, the precise number of cell EGs is difficult to 
determine, since it depends on the chosen threshold for impaired fitness of cell lines 
(Wang et al., 2015). Secondly, most of the genomic screens have been performed on 
human cancer cell lines with gene knockouts. Cases of discrepancy may occur when 
inferring organismal lethality from cancer cell survival rate. For example, the cancer cell 
line based assays can reveal oncogenes (Luo et al., 2008) which may not necessarily be 
essential in non-cancer cell lines. Therefore, careful examination and comparison of EGs 
inferred from lethality of knockout mice and viability of human cell lines is warranted as 
the catalog of known EGs grows continuously. 
In contrast to earlier studies which suggested that human disease genes tend to be non-
essential (Domazet-Loso and Tautz, 2008; Feldman et al., 2008; Goh et al., 2007; Park et 
al., 2008), my results are consistent with the conclusions from Dickerson et al. 
(Dickerson et al., 2011) and Georgi et al. (Georgi et al., 2013) that a major portion of 
human disease genes are essential. The enrichment of EGs among human disease genes 
from HGMD (Stenson et al., 2014) and genes neighboring GWAS hits (Welter et al., 
26 
 
2014) suggests that mutations in EGs contribute not only to Mendelian diseases, but also 
to complex traits and disorders. My results on the enrichment of EGs among different 
types of disease genes showed that while the contribution of EGs is widespread across 
disorders with various affected systems and underlying mechanisms, EGs seems to play 
an especially important role in early onset diseases. Homozygous loss-of-function 
mutations in EGs are not present in living individuals. While EGs are generally intolerant 
to other deleterious alleles at the population level, because of the functional importance 
of EGs, observed deleterious alleles in EGs are more likely to be pathogenic. I confirmed 
that EGs tend to demonstrate haploinsufficiency and an autosomal dominant model of 
inheritance (Dickerson et al., 2011; Georgi et al., 2013), which supports a potential 
cumulative effect of deleterious mutations (mostly in heterozygous state) in EGs on the 
risk of early onset complex disorders, such as ASD.  
Materials and Methods 
Identification of essential genes and non-essential genes 
I identified 3,023 protein-coding EGs annotated with 50 mouse phenotype (MP) terms, 
including prenatal, perinatal, and postnatal lethal phenotypes from the MGI (Eppig et al., 
2005) (Table S8). The MGI database was also used to extract 4,995 protein-coding NEGs 
with nonlethal phenotypes in the mouse. Phenotype data from the IMPC database portal 
(Koscielny et al., 2014) expanded the lethal gene list with the addition of 252 lethal genes 
and 101 genes with subviable phenotypes. I further supplemented the nonlethal gene list 
with 701 genes with viable phenotypes from the IMPC. In the case of discrepancy in the 
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reported lethality status between the MGI and the IMPC, I deferred to the phenotypes 
reported by the IMPC, because these mouse lines were generated on a defined C57BL/6N 
background and phenotypically characterized using a standardized pipeline. 
One to one mouse–human orthology of lethal and nonlethal genes was established based 
on MGI annotation and manual curation, resulting in 3,326 essential and 4,919 
nonessential human orthologs (NEGs). The catalog of EGs was further augmented with 
the addition of cell EGs from three recent studies (Blomen et al., 2015; Hart et al., 2015; 
Wang et al., 2015) aimed at the characterization of EGs in human cell lines. I obtained 
1,580 core EGs (genes above essentiality threshold in at least three of five cell lines in the 
study) from the work by Hart et al. (Hart et al., 2015), 1,739 core EGs (genes above 
essentiality threshold in at least two of four cell lines in the study) from the work by 
Wang et al. (Wang et al., 2015), and 1,734 core EGs (genes above essentiality threshold 
in at least one of two cell lines in the study) from the work by Blomen et al. (Blomen et 
al., 2015). By taking the overlap of three sets of core EGs, I obtained 956 high-
confidence human EGs. Among 956 EGs in human cell lines, 348 genes (36.4%) are also 
human orthologs of EGs in the mouse, 19 genes (2.0%) are human orthologs of NEGs in 
the mouse, and 589 genes (61.6%) have not been tested in the mouse. 
Identification of genes encompassing or surrounding disease- and trait-associated 
SNPs (‘GWAS hits’) 
6,384 protein-coding genes encompassing and/or neighboring disease- or trait-associated 
variants (‘GWAS genes’) were obtained from the GWAS Catalog (Welter et al., 2014) 
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(downloaded on April 29, 2016). Specifically, I used the ‘mapped genes’ from the 
GWAS Catalog, which are defined as the genes mapped to the strongest SNP from 
GWAS reports. The mapped genes are defined as the genes encompassing the GWAS 
SNP(s), (that is, located in coding or intragenic regions; n = 4,228) or the two genes that 
map upstream and downstream of the GWAS SNP(s) (that is, in intergenic regions; n = 
3,422). Enrichment of GWAS genes between our gene sets of interest was assessed by 
two-sided Fisher’s exact test.  
Categorization of human disease genes by the Human Phenotype Ontology 
I categorized human disease genes collected by the Human Phenotype Ontology Project 
(accessed the February 2017 release) (Kohler et al., 2017) based the subclasses of two 
ontology terms: “Phenotypic abnormality” (HP:0000118) and “Onset” (HP:0003674). As 
a result, I obtained 24 sets of disease genes annotated with abnormality in different 
organs or systems (i.e. “Abnormality of prenatal development or birth”,“ Abnormality of 
the breast”,“ Abnormality of the musculature”,“ Abnormality of limbs”,“ Abnormality of 
the voice”,“ Growth abnormality”,“ Abnormality of the respiratory system”,“ 
Abnormality of the skeletal system”,“ Abnormality of head or neck”,“ Abnormality of the 
digestive system”,“ Abnormality of the cardiovascular system”,“ Abnormality of the 
eye”,“ Abnormality of connective tissue”,“ Abnormality of the genitourinary system”,“ 
Neoplasm”,“ Abnormality of the nervous system”,“ Abnormality of the ear”,“ 
Abnormality of the integument”,“ Abnormality of the immune system”,“ Abnormality of 
blood and blood-forming tissues”,“ Abnormality of the endocrine system”,“ Abnormality 
of metabolism/homeostasis”,“ Constitutional symptom” and“ Abnormality of the thoracic 
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cavity”) , and 6 sets of genes annotated with different age of onset for their associated 
diseases (i.e. “congenital onset”, “neonatal onset”, “infantile onset”, “childhood onset”, 
“juvenile onset” and “adult onset”). For each set of disease genes, I evaluated the 
enrichment of 3,915 EGs vs. 4,919 NEGs using two sided Fisher’s exact test. For a 2 * 2 
contingency table with 4 cell counts: a (# EGs in target gene set), b (# EGs not in target 
gene set), c (# NEGs in target gene set) and d (# NEGs not in target gene set), the 95% 
confidence interval of odds ratio (OR) is calculated as follows: 
𝑒𝑒𝑒 [𝑙𝑛 (𝑂𝑂) ± 1.96 ∗ �1
𝑎
+ 1
𝑏
+ 1
𝑐
+ 1
𝑑
 ] 
Chromosomal distribution of essential genes 
The chromosomal distribution of 3,882 EGs with available coordinates in genome build 
hg19 was plotted using Phenogram 
(http://visualization.ritchielab.psu.edu/phenograms/plot). The enrichment of EGs across 
cytobands was assessed by Enrichr (Chen et al., 2013).  
Tissue specificity and ubiquitousness of gene expression 
For each expression dataset, we measure the Shannon entropy score as suggested by 
Schug et al.(Schug et al., 2005). The definition of tissue specificity score is shown below: 
Suppose the expression levels of relevant genes were measured in N tissues in an 
expression dataset, the relative expression level of gene g in tissue t was defined as: 
pt|g = wg,t / ∑1 ≤ t ≤ N wg,t 
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where wg,t  is the measured expression level of gene g in tissue t.  
The Shannon entropy (H) measuring the distribution of expression levels of gene g across 
all tissues in an expression dataset was defined as: 
Hg= ∑1 ≤ t ≤ N - pt|g log2(pt|g) 
The tissue specificity score of gene g in tissue t is calculated as: 
Qg|t = Hg - log2(pt|g) 
Analysis of haploinsufficiency of essential genes 
I collected genes sets from multiple studies and resources for the analysis of patterns of 
inheritance and haploinsufficiency of EGs. First, a catalog of human disease genes was 
obtained from Online Mendelian Inheritance in Man (OMIM; downloaded on July 12, 
2016) (Hamosh et al., 2005). From the OMIM catalog, I identified 1,411 genes annotated 
with genetic disorders that are “autosomal dominant” or “X-linked dominant” and 2,056 
genes annotated with genetic disorders that are “autosomal recessive” or “X-linked 
recessive.” By dissecting the above two gene lists, I obtained 1,000 genes underlying 
only dominant diseases, 1,645 genes underlying only recessive diseases, and 441 genes 
that were linked to both dominant and recessive disorders. Second, a list of 616 protein-
coding genes that were systematically assessed for evidence for dosage sensitivity was 
obtained from ClinGen Dosage Sensitivity Map (Rehm et al., 2015). Among 616 genes, 
239 genes were dosage-sensitive with sufficient evidence, 41 genes were dosage-
sensitive with some evidence, 47 genes were dosage-sensitive with little evidence, 200 
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genes had no evidence for dosage pathogenicity so far, and 89 genes were not dosage-
sensitive or with autosomal recessive phenotype. Third, a list of 262 haploinsufficient 
genes based on textmining from PubMed and OMIM was obtained from the work by 
Dang et al. (Dang et al., 2008). Fourth, from the MGI, I identified 313 human orthologs 
of mouse genes associated with heterozygous phenotypes. For each of the gene sets, I 
evaluated the enrichment of EGs compared with NEGs using Fisher’s exact test.  
I acquired the Haploinsufficiency Scores (Huang et al., 2010) and the Genome-Wide 
Haploinsufficiency Scores (Steinberg et al., 2015) for genome-wide prediction of the 
probability of haploinsufficiency. For each prediction model, the raw scores were ranked 
and converted to percentiles. The histograms and estimated density curves were plotted 
using ggplot2 (geom_histogram and geom_line) in R. 
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Figures 
 
Figure 2.1 Overlap between essential genes in human cells and human orthologs of 
essential genes in the mouse. Core essential genes in human cells identified in three 
studies: 1,580 (Hart et al., 2015), 1,739 (Wang et al., 2015), and 1,734 (Blomen et al., 
2015) (top row) (see Methods). Pie charts indicate overlap between core human cell-
essential genes and orthologous genes in the mouse: essential (EG, red); nonessential 
(NEG, green) and genes with unknown function in the mouse (Unknown, blue). 
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Figure 2.2 Enrichment of essential genes among HGMD human disease genes. (A) 
The fractions indicate the number of HGMD disease genes (disease-causing mutations 
(DM)) (n = 3,302) among 3,326 essential genes (EG, red); 4,919 nonessential genes 
(NEG, green) and 19,568 protein-coding genes (All, blue). Fisher’s exact test for 
enrichment: EG versus NEG (odds ratio = 2.00, P = 7.80 × 10−46), EG versus All (odds 
ratio = 3.13, P = 2.42 × 10−160), NEG versus All (odds ratio = 1.56, P = 1.83 × 10−29). (B) 
Essentiality status of 3,302 HGMD disease genes. 
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Figure 2.3 Enrichment of essential genes among genes neighboring GWAS hits. The 
fractions indicate the number of genes encompassing or neighboring GWAS hits (Welter 
et al., 2014) (n = 6,384) divided by essentiality status (EG in red, NEG in green, All in 
blue). Fisher’s exact test for enrichment: EG versus NEG (odds ratio = 1.16, P = 0.0015), 
EG versus All (odds ratio = 1.56, P = 5.80 × 10−31), NEG versus All (odds ratio = 1.35, P 
= 1.18 × 10−19). 
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Figure 2.4 Essential genes are intolerant to deleterious mutations. (A) Distribution of 
percentiles of the residual variation intolerance score (RVIS) across three classes of 
genes: EG (in red), NEG (in green) and All (in blue). Wilcoxon rank-sum test: EG versus 
NEG (P value < 2.2 × 10−16), EG versus All (P value < 2.2 × 10−16), NEG versus All (P 
value = 0.579). (B) Distribution of percentiles of the probability of being loss of function 
intolerant (pLI) across three classes of genes: EG (in red), NEG (in green) and All (in 
blue). Wilcoxon rank-sum test: EG versus NEG (P value < 2.2 × 10−16), EG versus All (P 
value < 2.2 × 10−16), All versus NEG (P value = 4.15 × 10−5). 
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Figure 2.5 Chromosomal distribution of 22 human orthologs of mutation-intolerant 
essential genes that are not currently included in the catalogs of Mendelian disease 
genes. Red bars indicate the chromosomal positions of the exhibited genes. 
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Figure 2.6 Chromosomal distribution of 3,915 human essential genes.  Chromosomal 
positions of EGs (hg19) are shown in red. Three chromosomal regions (17q21, 11q13 and 
16q22) with significant enrichment of EGs are shown in blue. 
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Figure 2.7 Chromosomal distribution of 3,879 essential genes in the mouse. 
Chromosomal positions of EGs (mm10) are shown in red. The chromosomal region 
(2qB) with significant enrichment of EGs is shown in blue. 
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Figure 2.8 Essentiality statuses of human diseases genes categorized by age of onset. 
The results (p values, odds ratios and 95% confidence intervals of odds ratios) of Fisher’s 
exact tests of enrichment of 3,915 EGs vs. 4,919 NEGs for human disease genes 
categorized by the age of onset of associated diseases were plotted. 
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Figure 2.9 Tissue expression specificity of EGs and NEGs. The distribution of 
Shannon entropy scores (Methods and Materials) for EGs (in red) and NEGs (in 
turquoise) was shown as both histogram and estimated density curve. The numbers of 
tissue-specific (entropy score<1.0) EGs are shown in the top bar plot. 
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Figure 2.10 Haploinsufficiency of essential genes. For each class of genes with 
different essentiality status (EG in red, NEG in turquoise, and unknown in gray), the 
proportion of genes among each gene set of interest is plotted in Left. Dosage-sensitive 
genes from ClinGen (Rehm et al., 2015) were classified into five categories (1, sufficient 
evidence; 2, some evidence; 3, little evidence; 4, no evidence and 5, not 
sensitive/recessive). Two-sided Fisher’s exact test was performed to assess the 
enrichment of EGs vs. NEGs, and the P values were indicated. The odds ratios for 
enrichment of EGs compared with NEGs and the 95% confidence intervals of odds ratios 
are plotted in Right. OMIM, Online Mendelian Inheritance in Man (Hamosh et al., 2005). 
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Figure 2.11 Distribution of genome-wide haploinsufficiency scores. Histograms and 
estimated density curves indicating the distribution of (A) the Haploinsufficiency Score 
(HIS) (Huang et al., 2010) and (B) the Genome-Wide Haploinsufficiency Score (GHIS) 
(Steinberg et al., 2015) across three gene sets, including EGs (red), NEGs (turquoise), 
and all protein-coding genes (56) (gray). EGs have significantly higher probability of 
exhibiting haploinsufficiency compared with NEGs (P value < 2.2 × 10−16 for both 
models; two-sided Wilcoxon rank sum test). 
 
  
43 
 
Tables 
Table 2.1 Mouse phenotype (MP) terms for lethal phenotypes. 
MP ID Lethality type Lethality description 
MP:0002058 neonatal lethality death within the neonatal period after birth (Mus: P0) 
MP:0002080 prenatal lethality death anytime between fertilization and birth (Mus: approximately E18.5) 
MP:0002081 perinatal lethality death anytime within the perinatal period (Mus: E18.5 through postnatal day 1) 
MP:0002082 postnatal lethality premature death anytime between the neonatal period and weaning age (Mus: P1 to approximately 3 weeks of age) 
MP:0006204 embryonic lethality before implantation 
death anytime between fertilization and implantation 
(Mus: E0 to less than E4.5) 
MP:0006205 
embryonic lethality 
between implantation and 
somite formation 
death anytime between the point of implantation and 
somite formation (Mus: E4.5 to less than E8) 
MP:0006206 
embryonic lethality 
between somite formation 
and embryo turning 
death anytime between somite formation and the 
initiation of embryo turning (Mus: E8 to less than E9) 
MP:0006207 embryonic lethality during organogenesis 
death anytime between embryo turning and the 
completion of organogenesis (Mus: E9-9.5 to less than 
E14) 
MP:0006208 lethality throughout fetal growth and development 
death anytime between the completion of organogenesis 
and birth (Mus: E14 to approximately E18.5) 
MP:0008527 embryonic lethality at implantation death due to failure of implantation (Mus: E4.5) 
MP:0008569 lethality at weaning premature death at weaning age, often due to the inability to make the transition to solid food 
MP:0008762 embryonic lethality death of an animal within the embryonic period prior to organogenesis (Mus: prior to E14) 
MP:0009850 
embryonic lethality 
between implantation and 
placentation 
death anytime between the point of implantation and the 
initiation of placentation (Mus: E4.5 to less than E9) 
MP:0010770 preweaning lethality death anytime between fertilization and weaning age (Mus: approximately 3-4 weeks of age) 
MP:0010831 partial lethality the appearance of lower than Mendelian ratios of 
offspring of a given genotype due to death of some, but 
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not all of the organisms 
MP:0010832 lethality during fetal growth through weaning 
death anytime between the completion of organogenesis 
and weaning age (Mus: E14 to approximately 3 weeks of 
age) 
MP:0011083 complete lethality at weaning 
premature death at weaning age of all organisms of a 
given genotype in a population, often due to the inability 
to make the transition to solid food 
MP:0011084 partial lethality at weaning 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms at weaning age 
MP:0011085 complete postnatal lethality 
premature death anytime between the neonatal period and 
weaning age of all organisms of a given genotype in a 
population (Mus: P1 to approximately 3 weeks of age) 
MP:0011086 partial postnatal lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms anytime between the neonatal 
period and weaning age (Mus: P1 to approximately 3 
weeks of age) 
MP:0011087 complete neonatal lethality death of all organisms of a given genotype in a population within the neonatal period after birth (Mus: P0) 
MP:0011088 partial neonatal lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms within the neonatal period after 
birth (Mus: P0) 
MP:0011089 complete perinatal lethality 
death of all organisms of a given genotype in a population 
within the perinatal period (Mus: E18.5 through postnatal 
day 1) 
MP:0011090 partial perinatal lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms within the perinatal period (Mus: 
E18.5 through postnatal day 1) 
MP:0011091 complete prenatal lethality 
death of all organisms of a given genotype in a population 
between fertilization and birth (Mus: approximately 
E18.5) 
MP:0011092 complete embryonic lethality 
death of all organisms of a given genotype in a population 
within the embryonic period prior to organogenesis (Mus: 
prior to E14) 
MP:0011093 complete embryonic lethality at implantation 
death of all organisms of a given genotype in a population 
at the point of implantation (Mus: E4.5) 
MP:0011094 complete embryonic 
lethality before 
death of all organisms of a given genotype in a population 
between fertilization and implantation (Mus: E0 to less 
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implantation than E4.5) 
MP:0011095 
complete embryonic 
lethality between 
implantation and 
placentation 
death of all organisms of a given genotype in a population 
between the point of implantation and the initiation of 
placentation (Mus: E4.5 to less than E9) 
MP:0011096 
complete embryonic 
lethality between 
implantation and somite 
formation 
death of all organisms of a given genotype in a population 
between the point of implantation and somite formation 
(Mus: E4.5 to less than E8) 
MP:0011097 
complete embryonic 
lethality between somite 
formation and embryo 
turning 
death of all organisms of a given genotype in a population 
between somite formation and the initiation of embryo 
turning (Mus: E8 to less than E9) 
MP:0011098 
complete embryonic 
lethality during 
organogenesis 
death of all organisms of a given genotype in a population 
between embryo turning and the completion of 
organogenesis (Mus: E9-9.5 to less than E14) 
MP:0011099 
complete lethality 
throughout fetal growth 
and development 
death of all organisms of a given genotype in a population 
between the completion of organogenesis and birth (Mus: 
E14 to approximately E18.5) 
MP:0011100 complete preweaning lethality 
death of all organisms of a given genotype in a population 
between fertilization and weaning age (Mus: 
approximately 3-4 weeks of age) 
MP:0011101 partial prenatal lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between fertilization and birth 
(Mus: approximately E18.5) 
MP:0011102 partial embryonic lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms within the embryonic period prior 
to organogenesis (Mus: prior to E14) 
MP:0011103 partial embryonic lethality at implantation 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms at the point of implantation (Mus: 
E4.5) 
MP:0011104 partial embryonic lethality before implantation 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between fertilization and 
implantation (Mus: E0 to less than E4.5) 
MP:0011105 
partial embryonic lethality 
between implantation and 
placentation 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between the point of implantation 
and the initiation of placentation (Mus: E4.5 to less than 
E9) 
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MP:0011106 
partial embryonic lethality 
between implantation and 
somite formation 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between the point of implantation 
and somite formation (Mus: E4.5 to less than E8) 
MP:0011107 
partial embryonic lethality 
between somite formation 
and embryo turning 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between somite formation and the 
initiation of embryo turning (Mus: E8 to less than E9) 
MP:0011108 partial embryonic lethality during organogenesis 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between embryo turning and the 
completion of organogenesis (Mus: E9-9.5 to less than 
E14) 
MP:0011109 
partial lethality throughout 
fetal growth and 
development 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between the completion of 
organogenesis and birth (Mus: E14 to approximately 
E18.5) 
MP:0011110 partial preweaning lethality 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between fertilization and weaning 
age (Mus: approximately 3-4 weeks of age) 
MP:0011111 
complete lethality during 
fetal growth through 
weaning 
death of all organisms of a given genotype in a population 
between the completion of organogenesis and weaning 
age (Mus: E14 to approximately 3 weeks of age) 
MP:0011112 partial lethality during fetal growth through weaning 
the appearance of lower than Mendelian ratios of 
organisms of a given genotype due to death of some, but 
not all of the organisms between the completion of 
organogenesis and weaning age (Mus: E14 to 
approximately 3 weeks of age) 
MP:0011400 complete lethality 
all individuals of a given genotype in a population die 
before the end of the normal lifespan but time(s) of death 
are unspecified 
MP:0013292 embryonic lethality prior to organogenesis 
death prior to the completion of embryo turning (Mus: 
E9-9.5) 
MP:0013293 embryonic lethality prior to tooth bud stage 
death prior to the appearance of tooth buds (Mus: E12-
E12.5) 
MP:0013294 prenatal lethality prior to heart atrial septation 
death prior to the completion of heart atrial septation 
(Mus: E14.5-15.5) 
E, embryonic day; Mus, Mus musculus. 
47 
 
Table 2.2 Human orthologs of mutation-intolerant essential genes that are not 
currently included in the catalogs of Mendelian disease genes. 
Gene Chrom Start End RVIS percentile pLI percentile 
ATP6V1B2 8 20197367 20226819 21.6 9.6 
CASC3 17 40140318 40172183 9.1 17.1 
CASZ1 1 10636604 10796650 13.6 3.4 
CHD4 12 6570083 6607476 0.7 0.6 
COG3 13 45464898 45536630 17.9 5.7 
CTR9 11 10750987 10779743 6.5 1.5 
DCP2 5 112976702 113020970 22.0 19.7 
DHX30 3 47802909 47850195 2.0 1.5 
FOXJ3 1 42176539 42335877 21.3 12.1 
MAT2A 2 85539165 85545280 19.3 23.7 
MYO18A 17 29073517 29180412 12.8 5.3 
NEMF 14 49782083 49853203 5.7 11.5 
PRDM10 11 129899706 130002835 15.6 6.9 
PREP 6 105277565 105403084 5.9 9.7 
RSBN1 1 113761832 113812476 13.0 21.4 
RUFY3 4 70704204 70807315 23.1 11.6 
SMC5 9 70258962 70354888 9.7 11.7 
SYNPO2 4 118850688 119061247 6.8 23.5 
TMEM63B 6 44126914 44155519 5.5 4.1 
ZMIZ2 7 44748581 44769881 4.9 4.9 
ZNF496 1 247297412 247331846 19.9 11.2 
ZNF536 19 30228290 30713538 1.1 13.5  
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Table 2.3 Essentiality status of human disease genes categorized by phenotypic abnormality. 
HPO ID Name # Genes 
# 
EGs 
# 
NEGs 
# 
Unknown 
OR 
OR1 95%CI 
low 
OR 95% CI 
high 
P value 
HP:0001197 
Abnormality of prenatal development 
or birth 
390 234 83 73 3.70 2.87 4.78 3.37E-27 
HP:0000769 Abnormality of the breast 230 135 58 37 2.99 2.19 4.08 4.16E-13 
HP:0003011 Abnormality of the musculature 1624 798 410 416 2.82 2.48 3.20 4.41E-60 
HP:0040064 Abnormality of limbs 1194 639 327 228 2.74 2.38 3.15 2.38E-47 
HP:0001608 Abnormality of the voice 215 114 55 46 2.65 1.92 3.67 1.47E-09 
HP:0001507 Growth abnormality 1470 735 397 338 2.63 2.31 3.00 2.18E-50 
HP:0002086 Abnormality of the respiratory system 1016 521 272 223 2.62 2.25 3.06 6.78E-37 
HP:0000924 Abnormality of the skeletal system 1839 909 528 402 2.51 2.24 2.83 7.10E-56 
HP:0000152 Abnormality of head or neck 1875 908 539 428 2.45 2.18 2.76 1.64E-53 
HP:0025031 Abnormality of the digestive system 1542 760 443 339 2.43 2.15 2.76 2.32E-45 
HP:0001626 
Abnormality of the cardiovascular 
system 
1418 700 422 296 2.32 2.04 2.64 1.36E-38 
HP:0000478 Abnormality of the eye 1755 825 522 408 2.25 2.00 2.53 8.36E-42 
HP:0003549 Abnormality of connective tissue 867 432 259 176 2.23 1.90 2.62 1.65E-23 
HP:0000119 
Abnormality of the genitourinary 
system 
1435 687 429 319 2.23 1.96 2.53 4.39E-35 
HP:0002664 Neoplasm 557 303 179 75 2.22 1.84 2.69 4.93E-17 
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HP:0000707 Abnormality of the nervous system 2336 1064 713 559 2.20 1.98 2.45 5.32E-49 
HP:0000598 Abnormality of the ear 1273 605 380 288 2.18 1.91 2.50 3.07E-30 
HP:0001574 Abnormality of the integument 1555 731 498 326 2.04 1.80 2.30 1.44E-30 
HP:0002715 Abnormality of the immune system 1083 503 365 215 1.84 1.60 2.12 2.55E-17 
HP:0001871 
Abnormality of blood and blood-
forming tissues 
827 385 279 163 1.81 1.55 2.13 2.62E-13 
HP:0000818 Abnormality of the endocrine system 798 386 281 131 1.81 1.54 2.12 3.03E-13 
HP:0001939 
Abnormality of 
metabolism/homeostasis 
1500 647 507 346 1.72 1.52 1.95 9.49E-18 
HP:0025142 Constitutional symptom 394 173 156 65 1.41 1.13 1.76 0.0022 
HP:0045027 Abnormality of the thoracic cavity 18 7 8 3 1.10 0.40 3.03 1 
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Table 2.4 Tissue-specific essential genes. 
Tissue # Genes Genes 
Testis 27 
LIN28A, DMBX1, FSHR, TRIM71, DPPA4, ZBTB20, NKX1-
1, GCM2, GCM1, PKD1L1, PAX4, C7orf55, FGF8, UTF1, 
SP7, FOXN4, RAD9B, POU4F1, HBZ, TEX19, SKOR2, 
DCC, C19orf67, MED26, C21orf59, TBX22, PLAC1 
Liver 15 
SERPINC1, APOB, PROC, SLC2A2, FGG, CYP7A1, SAA2, 
F2, CPB2, F7, CYP1A2, HP, APOH, SERPIND1, F9 
Muscle 12 
AMPD1 ,CACNA1S, MYOG, NEB, CHRNA1, MYL1, 
CHRNG, TAL2, MYF6, MYF5, ATP2A1, MYLPF 
Kidney 8 
NPHS2, SLC34A1, KCNJ1, GDF3, AQP2, SLC12A1, 
WNT9B, DNMT3L 
Brain 7 OTP,CALCR,CHAT,FGF3,GSX1,RTL1,AVP 
Pituitary 6 LMX1A,POMC,PROP1,LHX3,NEUROD4,RAX 
Adrenal 
Gland 
6 STAR,CYP11B2,CYP17A1,PHOX2A,CYP11A1,MC2R 
Pancreas 5 SPINK1,CLPS,PTF1A,IFITM5,INS 
Cells 5 CR1L,COL10A1,T,HMX3,PPAN 
Whole Blood 4 F11R,HBB,KLF1,ALAS2 
Thyroid 3 F11R,FOXE1,TSHR 
Small 
Intestine 
3 FGF19,MEP1B,P2RY4 
Heart 3 BMP10,MYL7,MYH6 
Lung 3 SFTPB,CSF2,SFTPA1 
Nerve 2 TMEM8C,FGF4 
Skin 2 HELT,KRT2 
Stomach 1 RFX6 
Spleen 1 SPIC 
Bladder 1 UPK2 
Colon 1 SLC26A3 
Prostate 1 SP8 
Esophagus 1 ERVFRD-1 
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Supplementary data 
Supplementary data 2.1 IMPC subviable genes with disease causing mutations in 
HGMD. 
Supplementary data 2.2 IMPC lethal genes with disease causing mutations in 
HGMD. 
Supplementary data 2.3 Catalog of EGs and NEGs. 
Supplementary data 2.4 Enrichment of EGs among genes within each cytoband in 
human genome build hg19. 
Supplementary data 2.5 Enrichment of EGs among genes within each cytoband in 
mouse genome build mm10. 
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CHAPTER 3: Cumulative effect of deleterious variants in essential 
genes on ASD risk 
Introduction 
Autism spectrum disorder (ASD) is a heterogeneous, heritable neurodevelopmental 
syndrome characterized by impaired social interaction, communication, and repetitive 
behavior (Huguet et al., 2013; State and Levitt, 2011). The highly polygenic nature of 
ASD (de la Torre-Ubieta et al., 2016; De Rubeis and Buxbaum, 2015; Willsey and State, 
2015) suggests that the analysis of the full spectrum of sequence variants in hundreds of 
genes will be necessary for deeper understanding of disrupted neuronal function. 
Prioritization of ASD risk genes initially focused on known pathways with recognized 
relevance to pathogenesis of ASD, such as synaptic function and neuronal development 
(Geschwind and Levitt, 2007). However, combined analyses of de novo, inherited, and 
case–control variation in over 2,500 ASD parent–child nuclear families identified around 
100 genes contributing to ASD risk (De Rubeis et al., 2014; Iossifov et al., 2014; Sanders 
et al., 2015), converging on pathways implicated in transcriptional regulation and 
chromatin modeling in addition to synaptic function. The early on-set of ASD suggests a 
prenatal origin of ASD. Multiple lines of evidence implicated that impairments of early 
brain development were involved in the pathogenesis of ASD (Parikshak et al., 2013; 
Stoner et al., 2014; Willsey et al., 2013a). 
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The main challenge in the current understanding of genetic architecture of ASD comes 
from a need to study the interplay between variants with a high effect (for example, 
recurrent de novo variants) and a background of variants with an intermediate effect but 
nevertheless, which still disrupt proper neuronal development. Essential genes (EGs) or 
genes that are necessary for successful completion of pre- and postnatal development are 
prime candidates for the source of this background or load of variants with a cumulative 
intermediate effect. EGs are highly enriched for human disease genes and under strong 
purifying selection (Georgi et al., 2013; Petrovski et al., 2013; Zhang et al., 2011). In 
addition to intolerance to loss-of-function , the functional impact of EGs is reflected by 
haploinsufficiency that is commonly observed in heterozygous mutations (Deutschbauer 
et al., 2005; Georgi et al., 2013). In addition to their role in defining a “minimal gene set” 
(Koonin, 2003; Mushegian and Koonin, 1996), EGs tend to play important roles in 
protein interaction networks (Hwang et al., 2009). Therefore, one may consider that EGs 
are involved in rate-limiting steps that affect a range of disease pathways (Chakravarti 
and Turner, 2016). 
A deeper understanding of the mutational spectrum of EGs in a neurodevelopmental 
disorder, such as ASD, is important, because EGs are less likely to be redundant, are 
more likely to have functional consequences when mutated, and may produce a gradation 
of phenotypes (White et al., 2013). Previous work by Georgi et al. reported an enrichment 
of EGs among genes with de novo mutations in ASD patients (Georgi et al., 2013). 
Several groups reported an enrichment of de novo and rare inherited single-nucleotide 
loss-of-function variants in ASD probands (Iossifov et al., 2014; Krumm et al., 2015), 
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although there is a depletion of damaging mutations in ASD risk genes in population 
controls (Iossifov et al., 2015; Petrovski et al., 2013; Samocha et al., 2014). With the 
most comprehensive list of human EGs to our knowledge, I extended the analysis to both 
de novo and inherited damaging variants in 1,781 ASD families. In addition to disease 
status, I further showed the effect of damaging variants in EGs on ASD-related traits, 
such as the social skill measurement in 2,348 ASD probands. Finally, I performed 
coexpression analysis of EGs in the developing human brain to identify clusters of 
interacting EGs that contribute to ASD risk and suggest ASD candidate genes. 
Results 
Increased burden of deleterious mutations in essential genes in ASD probands 
To address a possible cumulative effect of variants in EGs in ASD in a larger cohort of 
1,781 ASD quartet families (with 1,781 probands and 1,781 siblings) from the Simons 
Simplex Collection (Fischbach and Lord, 2010), I acquired de novo and rare inherited 
mutations from the exome sequencing data of these families (Iossifov et al., 2014; 
Krumm et al., 2015). I examined the individual mutational burden defined by the number 
of de novo loss-of-function (dnLoF), de novo nonsynonymous damaging (dnNSD), and 
inherited rare damaging (inhRD) mutations per individual (Supplementary data 3.1 and 
3.2). On average, an ASD proband carried 0.06 dnLoF, 0.21 dnNSD, and 10.74 inhRD 
mutations in EGs. The mutational burden in EGs was significantly elevated in ASD 
probands compared with unaffected siblings for the three classes of variants considered 
(P value = 4.75 × 10−7 for dnLoF, P value = 3.41 × 10−4 for dnNSD, and P value = 0.017 
for inhRD; one-sided Wilcoxon signed ranked test) (Figure 3.1 and Table 3.1). In 
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contrast, no significant difference in mutational burden in NEGs was observed (P value = 
0.10 for dnLoF, P value = 0.069 for dnNSD, and P value = 0.75 for inhRD) (Table 3.1). 
Interestingly, 10,823 genes that are currently not assigned as EG or NEG (i.e., 
phenotypically uncharacterized in mouse knockouts and human cell-based assays) have a 
moderately elevated burden of dnLoF but not dnNSD and inhRD variants in ASD 
probands (P value = 0.0042) (Table 3.1). Notably, the effect sizes of EG burden in each 
variant type correspond to our understanding of the severity of the variant type; de novo 
mutations, which are expected to have a larger functional impact, also display the 
strongest difference between ASD probands and unaffected siblings (effect size = 0.117 
for dnLoF; effect size = 0.079 for dnNSD; Cohen’s d). In contrast, inherited mutations 
are expected to have a moderate functional impact, and a smaller difference is observed 
between probands and siblings (effect size = 0.042 for inhRD). Although I observed 
marginally increased burden of dnLoF and dnNSD mutations in EGs in female (n = 325) 
compared with male (n = 2,043) probands (Table 3.2), the analysis of families divided by 
gender of proband–sibling pairs (female–female, male–female, female–male, and male–
male) showed that gender bias does not underlie the observed differences in mutational 
burden between probands and siblings (Table 3.3). 
The effect of rare damaging mutations in essential genes on social and cognitive 
impairments 
To evaluate the effect of rare damaging mutations in EGs on ASD-associated traits, we 
used the available quantitative phenotype data on social and cognitive impairments in 
∼2,500 ASD families from Simons Simplex Collection (Iossifov et al., 2014; Krumm et 
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al., 2015) (Supplementary data 3.3). As a measure of sociability, I used the total raw 
score from the Social Responsiveness Scale (SRS) (Constantino and Gruber, 2005), and 
as cognitive measures, I used three different intelligence quotient (IQ) scores (full-scale 
IQ, verbal IQ, and nonverbal IQ). As previously reported (Constantino et al., 2003), SRS 
scores were unrelated to IQ, especially in subjects with IQ higher than 50 (Figure 3.2). In 
male probands, I observed that the mutational burden in EGs was positively correlated 
with the SRS total raw score (P value = 1.08 × 10−6; Poisson regression) (Table 3.4). The 
effect was not significant in NEGs (P value = 0.21). In female probands, mutational 
burden in NEGs but not EGs was negatively correlated with SRS total raw score (P value 
= 0.085 for EG and P value = 6.06×10-6 for NEG). In addition, I found that mutational 
burden in both EGs and NEGs had a significant effect (P value < 2.2 × 10−16) on verbal 
and nonverbal IQ scores and that the effect sizes of mutational burden in EGs and NEGs 
were comparable (Table 3.5). These results suggest that, in ASD probands, deleterious 
variants in EGs contribute to decreased social skills in males, whereas deleterious 
variants in both EGs and NEGs lead to decreased IQ.  
The overlap between essential genes and known ASD risk genes 
To initially explore the overlap between EGs and known ASD genes, I examined the 
essentiality status of ∼500 ASD candidate genes from the Simons Foundation Autism 
Research Initiative (SFARI) AutDB database (updated December of 2015) (Abrahams et 
al., 2013) (Figure 3.3). Compared with NEGs, EGs were enriched among ASD 
candidates categorized as “syndromic” (category S: odds ratio = 3.95, P value = 0.0003; 
two-sided Fisher’s exact test), candidates with “high confidence” (category 1: odds ratio 
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= 15.12, P value = 0.0004), and candidates with “suggestive evidence” (category 3: odds 
ratio = 2.14, P value = 0.0006). Trends of enrichment of EGs were also observed for 
“strong candidates” (category 2: odds ratio = 1.62, P value = 0.21). I did not observe 
enrichment of EGs among candidate genes with less supportive evidence (categories 4–
6). 
To further address whether EGs contribute to ASD risk, I compared the strength of ASD 
association signals between EGs and NEGs in data from a recent comprehensive analysis 
of ASD genomic architecture (Sanders et al., 2015), where the transmission and de novo 
association (TADA) test (He et al., 2013) was used to evaluate ASD association based on 
combined evidence from de novo single nucleotide variants (SNVs), de novo small 
deletions, and rare inherited variants from Simons Simplex Collection cohorts as well as 
case–control data from Autism Sequencing Consortium (ASC) cohorts (Buxbaum et al., 
2012). There was a significant enrichment of EGs compared with NEGs in 65 high-
confidence TADA ASD genes [TADA false discovery rate (FDR) q values < 0.1] 
identified by Sanders et al. (Sanders et al., 2015) (36 EGs vs. 15 NEGs; odds ratio = 3.03, 
P value = 1.82 × 10−4; one-sided Fisher’s exact test). In a broader set of 441 “potential” 
TADA ASD genes (TADA FDR < 0.5), EGs were also enriched compared with NEGs 
(132 EGs vs. 117 NEGs; odds ratio = 1.43, P value = 0.00537). Furthermore, by 
comparing the observed TADA FDR with the expected TADA FDR, I detected a strong 
deviation from the null distribution in EGs, especially in 132 EGs with potential ASD 
association (TADA FDR < 0.5) (Figure 3.4). In contrast, NEGs were not enriched for 
association relative to the background expectation, suggesting that the association signals 
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between EGs and ASD were stronger and less likely to be false positive compared with 
NEGs. 
The spatio-temporal expression specificity of essential genes in human brain 
To explore the spatio-temporal expression specificity of EGs in human brain, I performed 
Cell type-Specific Expression Analysis (CSEA) (Xu et al., 2014) of EGs and NEGs based 
on BrainSpan RNA-seq data  across 6 brain regions and 10 developmental stages and 
ages (Table 3.6). Strikingly, I observed distinct temporal patterns of expression 
specificity between EGs and NEGs (Figure 3.6). In six brain tissue types (amygdala, 
cerebellum, cortex, hippocampus, striatum and thalamus), EGs were enriched for genes 
specifically expressed in brain at early developmental stages (from early to mid-fetal) 
while NEGs were enriched for genes specifically expressed in brain at later stages (from 
late fetal to young adulthood). For each set of EGs which were specifically expressed, I 
evaluated the enrichment of 441 potential ASD genes (FDR < 0.5) from Sanders et al. 
(Sanders et al., 2015) (Figure 3.7; Table 3.6). Significant enrichment was found in early 
mid fetal cortex (p-value=2.17 ×10-6; One-sided Fisher’s exact test) and early mid fetal 
striatum (p-value=1.77 ×10-4; One-sided Fisher’s exact test). This finding agrees with 
recent studies using different approaches which suggested key brain regions involved in 
the pathogenesis of ASD during early to mid-fetal development (Parikshak et al., 2013; 
Willsey et al., 2013b; Xu et al., 2014). Moderate enrichment was also found in early fetal 
cortex, early fetal cerebellum and late mid fetal cortex. In contrast, specifically expressed 
NEGs showed no enrichment. 
59 
 
Coexpression modules in the developing human brain 
It is our hypothesis that a cumulative effect of deleterious variants in several EGs, within 
the same pathway or across pathways may underlie impaired brain development and 
individual’s ASD risk. To identify clusters of potentially interacting genes, I evaluated 
the spatiotemporal expression of EGs and NEGs using RNA sequencing (RNA-seq) data 
from BrainSpan . I identified 41 coexpression modules with distinct expression patterns 
across 16 brain regions and 31 pre- and postnatal time points (Figure 3.8). I observed that 
the majority of EG-enriched modules (11 of 14; FDR < 0.1; two-sided Fisher’s exact test) 
(Figure 3.8 and 3.9; Table 3.7) exhibited an “early-expression” pattern, where the 
expression levels were higher at early fetal stages (starting from 8 postconceptual weeks) 
and gradually declined before birth. In contrast, the majority of the NEG-enriched 
modules (15 of 18) exhibited a “later-expression” pattern, with expression levels that 
were lower at early fetal stages and gradually increased until birth. 
I found that EGs in three EG-enriched modules (M01, M02, and M16) were significantly 
enriched (FDR < 0.1; one-sided Fisher’s exact test) for 441 potential TADA ASD genes 
(Figure 3.9). Notably, all of the three modules were also EG-enriched and early-
expressed across fetal brain regions (Figure 3.9 and 3.10). From the pathway enrichment 
analysis of these EG-enriched modules in the Reactome database (Croft et al., 2014; 
Fabregat et al., 2016), I found that the top pathways enriched included “transcription” 
(M01), “chromatin modifying enzymes and chromatin organization” (M02), and “axon 
guidance” (M16) (Table 3.8), in agreement with the insights from recent large-scale 
autism studies showing that genes for synaptic formation, transcriptional regulation, and 
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chromatin remodeling are disrupted in autism (De Rubeis et al., 2014; Iossifov et al., 
2014; Sanders et al., 2015). This combined analysis identified 974 EGs from three 
modules that are coexpressed with known ASD candidate genes at distinct stages of brain 
development. 
29 essential genes as strong candidates for ASD 
To further prioritize known EGs as candidates for ASD, I constructed a coexpression 
network for 974 EGs from three modules enriched for potential ASD genes (Figure 3.10); 
844 genes among 974 have a close interaction with high-confidence ASD genes 
(connected to at least two genes with TADA FDR < 0.1), and 370 genes harbor de novo 
or inherited loss-of-function mutations in ASD individuals from Simons Simplex 
Collection or ASC cohorts. Of these, 52 have a TADA FDR less than 0.5. Among 52 
genes, 23 have been previously shown to contribute to ASD risk [categories syndromic 
(S), 1, 2, 3, and 4 in SFARI]. For the remaining 29 EGs that have not yet been linked to 
ASD risk, I argue that, based on (i) the importance of EGs in ASD etiology as shown by 
their role in critical developmental stages and the increased burden of rare, damaging 
mutations in ASD individuals; (ii) their coexpression with high-confidence ASD genes in 
brain; and (iii) the suggestive genetic evidence from the TADA analysis, these 29 EGs 
represent the strongest candidates for additional investigation in their role in ASD (Figure 
3.11 and Table 3.8). According to available mouse phenotypes from the MGI (Eppig et 
al., 2005) and the IMPC (Koscielny et al., 2014), 11 of these 29 EGs have reported 
heterozygous phenotypes in mice (Table 3.9). Among them, four EGs (CHD1, FBXO11, 
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KDM4B, and VCP) have been associated with abnormal neural development and/or 
behavioral phenotypes in heterozygotes. 
Discussion 
I provided multiple lines of evidence suggesting that deleterious variants in EGs have a 
cumulative effect on ASD risk. Using a comprehensive list of 3,915 EGs, I showed that 
there is both an elevated burden of damaging mutations in EGs in ASD probands and also 
an enrichment of EGs in the recently identified high-confidence ASD-associated genes. 
Moreover, the analysis of EGs in the developing brain identified clusters of coexpressed 
EGs implicated in ASD, including 29 EGs functionally related to previously identified 
ASD risk genes. 
I find that ASD individuals have a higher burden of mutations in EGs compared with 
their unaffected siblings. It is notable but not surprising that this effect is particularly 
pronounced when considering de novo mutations, because this class of mutations is only 
subject to selection pressure after originating in the individual, and has exhibited some of 
the most prominent associations with the risk of ASD (Iossifov et al., 2014; Iossifov et 
al., 2012; O'Roak et al., 2012b; Sanders et al., 2012) . Similarly, a moderately increased 
burden of dnLoF variants in ASD probands was detected with a group of 10,823 
phenotypically uncharacterized genes. Based on current estimates, one-fifth of these 
uncharacterized genes (∼2,000) are expected to be EGs, which may explain the higher 
mutational burden of dnLoF variants in ASD probands. Recent studies have begun to 
show that additional genetic factors, such as rare and common inherited variations, also 
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contribute to ASD (Gauglerl et al., 2014; Krumm et al., 2015). My results support this 
finding, showing that inherited, rare, damaging mutations in EGs also have a significant 
effect on ASD risk. Furthermore, I show an EG-specific effect on social responsiveness, a 
measure of the social aspects of ASD. In contrast, mutational burden in both EGs and 
NEGs has an effect on IQ measures. Complex social behaviors result from a range of 
different cognitive processes; however, in ASD subjects, there is a striking dissociation in 
the level of impairment in social interaction or communication and general cognitive 
abilities (as measured by IQ) (Constantino et al., 2003). Moreover, studies in model 
organisms clearly show a fetal origin for social behavior deficits (Belinson et al., 2016). 
My results are in line with these findings and suggest that, although a higher mutational 
burden over all genes may have consequences on IQ, mutational burden in a set of genes 
with a role at critical early developmental stages influences the development of social 
behavior. Moreover, my findings are also further supported by the recent report that 
genomic regions that are under accelerated evolution have essential functions in the 
human brain development and, when mutated, may cause increased risk for autism (Doan 
et al., 2016). Therefore, understanding the regulatory landscape of dosage-sensitive EGs 
expressed at critical stages of brain development may reveal risk alleles for many 
neurodevelopmental and psychiatric disorders.  
The analysis of the overlapping set of Simons Simplex Collection ASD families by 
several groups using complementary approaches led to the identification of around 100 
ASD risk genes and the finding of a depletion of damaging mutations in ASD risk genes 
(Iossifov et al., 2015; Petrovski et al., 2013; Samocha et al., 2014). I show that a 
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significant number of reported ASD risk genes are essential for survival and fitness and 
therefore have a distinctive mutational spectrum, providing a biological foundation for 
this intolerance to damaging mutations. Of the spectrum of existing alleles, homozygosity 
or compound heterozygosity for loss-of function alleles will never be observed. Also, 
because of synthetic lethality, some combinations of mutations in EGs are eliminated. 
Therefore, individuals will have only a subset of “milder” coding or regulatory alleles. 
The current list of candidate genes consists of 100 (high-confidence ASD genes) to 400 
genes (potential ASD genes) (Sanders et al., 2015). It is striking that my study provides 
strong statistical evidence for the aggregate effect across 3,915 EGs impacting risk for 
this neurodevelopmental disorder. A recent SNP-based heritability study reported the 
extreme polygenicity of schizophrenia, with 70% of 1-Mb genomic regions harboring 
schizophrenia risk alleles (Loh et al., 2015). Assuming a similar genetic architecture in 
ASD and schizophrenia, genomic maps of EGs with “surviving” deleterious and 
regulatory variants in ASD probands represent a complementary approach for the 
analysis of combinations of culprit genes or alleles.  
Because of the fundamental functional role of EGs in an organism, genetic variants in 
these genes are likely to contribute to many traits and diseases as reflected by the 
previous finding that EGs are enriched for human disease genes (Dickerson et al., 2011; 
Dickinson et al., 2016; Georgi et al., 2013). My study is focused on a specific 
neurodevelopmental disorder—ASD—because it has been suggested that ASD has its 
roots in abnormalities in prenatal brain development (Hazlett et al., 2017; Parikshak et 
al., 2013; Stoner et al., 2014; Willsey et al., 2013a). Specifically, my analysis of the 
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temporal expression patterns of coexpressed gene modules in the developing brain shows 
that genes in three EG-enriched coexpression modules implicated in ASD are expressed 
at a high level at the earliest stages of brain development, as early as 8 weeks after 
conception. In contrast, at later stages of brain development, the expression levels of 
genes in these EG-enriched modules decrease, whereas the expression levels of genes in 
NEG-enriched modules increase. The potential role of EGs in ASD is further supported 
by the analysis of the spatio-temporal expression specificity of essential genes in human 
brain, which showed that EGs specifically expressed in brain tissues converged at key 
brain regions (including cortex and striatum) involved in the pathogenesis of ASD 
(Parikshak et al., 2013; Willsey et al., 2013b; Xu et al., 2014) during early to mid-fetal 
development. These findings suggest that EGs have a distinctive influence at some of the 
earliest brain developmental stages as previously reported for constrained genes (Choi et 
al., 2016) and genes in functional networks perturbed in ASD (Chang et al., 2015). 
However, to further confirm the distinct contribution of EGs to early onset diseases, a 
comparison of the burden of deleterious variants in EGs across other complex disorders, 
including those with a later onset, is warranted. 
Each individual can carry a number of deleterious mutations, each of which can have a 
small effect. Because brain function may be particularly sensitive to mutation 
accumulation, identifying a specific set of genes in which mutations have a behavioral 
effect will assist us in understanding how mutation accumulation within an individual can 
result in a phenotype, such as ASD. Hallmarks of ASD are phenotypic heterogeneity, 
frequent comorbidities, and that no specific brain region or cell type is uniquely 
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implicated (de la Torre-Ubieta et al., 2016), further supporting the role of genes with a 
global effect on embryonic and fetal development. Here, I provide evidence that genes 
that are essential for survival and fitness also contribute to ASD risk and lead to the 
disruption of normal social behavior. 
Materials and Methods 
Burden analysis of mutations in EGs in ASD families 
The Simons Simplex Collection contains genetic and phenotypic information from 2,600 
ASD families, each of which has one child affected with ASD and unaffected parents and 
siblings (Fischbach and Lord, 2010). ASD probands were defined by clinical consensus 
from the Autism Diagnostic Interview–Revised (Lord et al., 1994) and the Autism 
Diagnostic Observation Schedule (Lord et al., 2000). Multiple individual phenotypic 
measures, including the Social Responsiveness Scale (SRS) (Constantino and Gruber, 
2005) and IQ, were available (Iossifov et al., 2014; Krumm et al., 2015) .  
I aimed to investigate the impact of both de novo and rare inherited variants in EGs on 
ASD risk. I acquired a list of 5,648 de novo variants from an exome sequencing study on 
2,517 ASD families from the Simons Simplex Collection (Iossifov et al., 2014) and an 
additional list of 1,544 de novo variants from a reanalysis of the same cohort (2,377 ASD 
families) with a different pipeline (Krumm et al., 2015). Among 7,192 de novo variants, 
674 were loss-of-function mutations (i.e., SNVs that are frameshift, stop-loss, stop-gain, 
start-loss, splicing donor or acceptor, and frameshift indels), and 3,462 were 
nonsynonymous mutations (i.e., missense SNVs and nonframeshift indels). The 
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deleterious de novo nonsynonymous mutations were selected using a threshold of the 
Combined Annotation-Dependent Depletion (CADD) (Kircher et al., 2014) phred-scale 
score above 10. In addition, I obtained 249,729 rare inherited mutations from 2,377 ASD 
families (Krumm et al., 2015). From the variants successfully called by both GATK 
(McKenna et al., 2010) and FreeBayes (Garrison and Marth, 2012), I extracted loss-of-
function mutations and nonsynonymous mutations with minor allele frequency in Exome 
Variant Server (European ancestry)  less than 0.01 and CADD phred-scale score above 
10. At the end of the variant filtering steps, I obtained 372 dnLoF variants, 1,497 dnNSD 
variants, and 77,891 inhRD variants in EGs or NEGs for mutational burden analysis 
(Supplementary data 3.1 and 3.2). 
The individual mutational burden was defined as the number of mutations carried by each 
subject in the gene sets of interest (i.e. 3,915 EGs and 4,919 NEGs) for each class of 
variants (dnLoF, dnNSD, and inhRD). Among all Simons Simplex Collection ASD 
families, there were 1,781 ASD quartets where exome sequence data from an affected 
proband and an unaffected sibling were available. The individual mutational burden in 
1,781 ASD probands was compared with the burden in their unaffected sibling using one-
sided Wilcoxon signed ranked test. The effect sizes were represented by cohen’s D. The 
95% confidence interval of effect size was estimated by a bootstrapping procedure, i.e. 
the 2.5 percentile and 97.5 percentile of the pool of effect sizes from 1000 resampled data 
sets generated from the original data set. In each resampled data set, the pairs of siblings 
were randomly selected with replacement. 
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I acquired SRS total raw scores for 2,348 probands and 1,678 siblings as well as 
verbal/nonverbal IQs for 2,359 probands for 1,781 ASD quartets and 587 ASD trios from 
Simons Simplex Collection families (Supplementary data 3.3). Poisson regression 
analysis was carried out separately between each trait (i.e., SRS total raw score and 
verbal IQ and nonverbal IQ) as the dependent variables and the individual burdens of all 
rare damaging mutations (including dnLoF, dnNSD, and inhRD) in EGs or NEGs as the 
independent variables. 
Comparison between observed and expected TADA FDR q values 
To compare the strength of association signals to ASD between EGs and NEGs, FDR q 
values for the TADA test of 18,665 genes were obtained from the work by Sanders et al. 
(Sanders et al., 2015). For each gene set of interest (i.e., 3,915 EGs or 4,919 NEGs), the 
null distribution of the transmission and de novo association test (TADA) (He et al., 
2013) FDR q values was generated by randomly resampling with replacement. Within 
one iteration of the resampling procedure, the TADA FDR q value of a random gene 
from the tested 18,665 genes was obtained for each gene in the gene set of interest. The 
resampled TADA FDR q values were then ranked from low to high. The resampling 
procedure was repeated for 100,000 iterations. For each observed TADA FDR q value 
ranked from low to high, the median of 100,000 resampled q values with the same rank 
was considered the expected TADA FDR q value. The 2.5th and 97.5th percentiles of 
100,000 resampled q values were considered the estimated 95% confidence intervals of 
each expected TADA FDR q value. The observed FDR q values were then compared 
with the expected FDR q values. 
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Construction of Coexpression Modules and Coexpression Network in Brain 
Coexpression analysis in human brain was conducted based on RNA-seq data from 
BrainSpan: Atlas of the Developing Human Brain . We used the Weighted Correlation 
Network Analysis (WGCNA) package (Langfelder and Horvath, 2008) for data quality 
control and identification of modules of coexpressed genes. The expression data for 
52,376 Ensembl genes (Flicek et al., 2014) (including protein-coding genes, noncoding 
genes, or pseudogenes) across 525 samples were obtained; 1,716 genes with too many 
missing entries or zero variance in expression levels were removed by the “good-
SamplesGenes” function in the WGCNA, and 12,613 genes with very low expression 
levels [maximum reads per kilobase of transcript per million mapped reads (RPKM) less 
than 0.5 across samples] were removed. As a final step for gene-level data cleaning, only 
protein-coding genes were selected for additional analysis. For sample-level data 
cleaning, three outlier subjects (300, 303, and 306) were removed according to subject-
level clustering result. Ten brain tissue types (caudal ganglionic eminence, cerebellum, 
dorsal thalamus, lateral ganglionic eminence, medial ganglionic eminence, occipital 
neocortex, parietal neocortex, primary motor sensory cortex, temporal neocortex, and 
upper rhombic lip) with data from fewer than 10 developmental stages were removed. 
The final quality-controlled dataset consisted of expression levels of 15,952 protein-
coding genes in 16 brain tissue types across 31 pre- and postnatal developmental stages 
(495 samples in total). For module detection, we used the “blockwiseModules” function 
in the WGCNA with default parameters, except for the network type (power = 6, 
deepSplit = 2, and networkType = “signed”). I used the signed version of coexpression 
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analysis that links two genes with positive correlation of expression levels. Coexpression 
between gene pairs was calculated based on the quality-controlled BrainSpan RNA-seq 
data with 495 brain samples. Two genes were defined as “coexpressed” in the brain if the 
Pearson correlation of the expression levels of both genes across 495 brain samples was 
greater than or equal to 0.8. In total, there were 8,600,150 coexpression links among 
protein-coding genes. The coexpression network was created using the GeneMania 
plugin (Mostafavi et al., 2008) within Cytoscape 3.2.1 (Shannon et al., 2003). Of 974 
EGs from three modules (M01, M02, and M16) implicated in ASD, coexpression data 
were available for 973 genes, which were used as the input gene set for network 
construction. The coexpression network consists of a main connected component with 
963 nodes and 187,443 edges as well as 10 isolated nodes. 
Pathway enrichment analysis 
I performed pathway enrichment analysis in the Reactome database (Fabregat et al., 
2016) using Enrichr (Chen et al., 2013) for three EG-enriched modules (M01, M02, and 
M16) that were also enriched for potential ASD genes. The enriched pathways were 
ranked by P values with Benjamini–Hochberg adjustment [False discovery rate (FDR) q 
values] from the Fisher’s exact test. 
The cell type-specific expression analysis (CSEA)  
The cell type-specific expression analysis (CSEA) was performed using the SEA on-line 
tool ( http://genetics.wustl.edu/jdlab/csea-tool-2/) (Xu et al., 2014) with lists of 3,915 
EGs and 4,919 NEGs as input, among which the SEA analysis were available for 3,838 
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EGs and 4,757 NEGs. The returned p-values and lists of enriched genes with the 
threshold of specificity index thresholds (pSI) < 0.05 were used for analysis. 
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Figures 
 
Figure 3.1 Individual mutational burden analysis in 1,781 pairs of ASD probands 
and unaffected siblings. The analyses were performed separately for 3,915 EGs (red) 
and 4,919 NEGs (turquoise). The individual mutational burden is defined by the number 
of dnLoF, dnNSD, and inhRD mutations per individual. Effect sizes were measured by 
Cohen’s d, which is defined as the difference between both means divided by the SD of 
the paired differences. The estimated 95% confidence intervals of effect sizes were 
plotted. P values were obtained from one-sided Wilcoxon signed ranked test. *P value < 
0.05. 
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Figure 3.2 Correlation between SRS and IQ. For each of 2,368 ASD probands from 
Simons Simplex Collection, the Pearson correlation between SRS total raw scores and 
three IQ scores (full-scale IQ, verbal IQ, and nonverbal IQ) was plotted. The probands 
were divided by IQ scores: (A, C, and E) IQ< 50 and (B, D, and F) IQ ≥ 50. 
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Figure 3.3 Essentiality statuses of SFARI ASD candidate genes. ASD candidate genes 
categorized by SFARI genes scores [S (syndromic); 1, high confidence; 2, strong 
candidate; 3, suggestive evidence; 4, minimal evidence; 5, hypothesized; and 6, not 
supported] (Abrahams et al., 2013) and their essentiality status (EG in red, NEG in 
turquoise, and unknown in gray). ***The P value from two-sided Fisher’s exact test (EG 
vs. NEG) is less than 0.001. 
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Figure 3.4 The distribution of TADA FDR q values of EGs and NEGs. The FDR q 
value of the TADA test evaluates ASD association based on combined evidence from de 
novo SNVs and small deletions, rare inherited variants, and variants (9). The observed 
negative log10 (q) values of 3,915 EGs (red) and 4,919 NEGs (turquoise) are compared 
with the expected counterparts under the null hypothesis. The dashed lines indicate the 
FDR thresholds (FDR = 0.1 in red and FDR = 0.5 in blue) for identification of ASD risk 
genes. The 95% confidence intervals of the expected negative log10 (q) values are shaded 
in gray. 
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Figure 3.5 Expression profiles of 41 coexpression modules in the brain. Expression 
profiles of genes from 41 coexpression modules based on the RNA-seq data from 
BrainSpan  are shown. The y axis represents the first principle component of the module-
level expression profiles in each brain tissue type. The x axis represents developmental 
stages in chronological order (Figure 3.7 shows the labels of the time points). The vertical 
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dashed lines indicate the time of birth. The total number of protein-coding genes in each 
module (n) is indicated along with the module name. 
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Figure 3.6 Spatio-temporal specific expression of essential genes and non-essential 
genes. The sizes of dots indicate –log10 of p-values from the specific expression analysis 
(SEA) on-line tool ( http://genetics.wustl.edu/jdlab/csea-tool-2/) (Xu et al., 2014) for 
3,915 EGs (in red) and 4,919 NEGs (in turquoise) separately. Each number below red 
dots indicate the number of specifically expressed EGs in the corresponding brain tissue 
(x axis) and developmental stage (y axis). 
79 
 
 
Figure 3.7 Enrichment for potential ASD genes among region- and time-specifically 
expressed EGs. The heatmap shows the negative log10(p) values for enrichment of 441 
potential ASD risk genes (Sanders et al., 2015)  in each set of EGs specifically expressed 
in each brain region (on the x-axis) and developmental stage (on the y-axis). The negative 
log10 (p) values for combinations of brain regions and developmental stages with 
significant enrichment of potential ASD genes (p-value<0.05 with Bonferroni correction; 
one-sided Fisher’s exact test) are noted. 
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Figure 3.8 Coexpressed modules enriched in EGs and NEGs. The upper barplot 
displays the level of enrichment of EGs vs. NEGs for each of 41 coexpression modules 
based on BrainSpan RNA-seq data. The lower barplot displays the level of enrichment 
(green) of 441 potential ASD genes in EGs from 41 coexpression modules. The heights 
of the bars represent negative log10 (FDR q value). The upper and lower red dashed lines 
indicate FDR q value threshold of 0.1. 
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Figure 3.9 The brain expression trajectories of genes from three coexpression 
modules implicated in ASD. The expression trajectories in brain for 1,601 genes in M01 
(orange), 1,150 genes in M02 (purple), and 347 genes in M16 (green) were fitted based 
on the first principle components of the module level expression profiles (y axis). The x 
axis represents developmental stages in chronological order. The vertical dashed line 
indicates the time of birth. pcw, Postconceptual week. 
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Figure 3.10 Co-expression network of essential genes from three modules implicated 
in ASD. Coexpression network of 973 of 973 EGs from M01 (orange), M02 (purple), and 
M16 (green). Edges indicate coexpression between gene pairs. 
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Figure 3.11 Chromosomal distribution of 29 EGs suggested as strong ASD 
candidate genes. The locations of each gene along the chromosomes are shown in red. 
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Tables 
Table 3.1 Mutational burden analysis in 1,781 ASD quartet families. 
Variant 
Type Gene Set 
# 
Genes 
Proband 
Average 
Sibling 
Average Effect Size 
Effect Size 
95% CI Low 
Effect Size 
95% CI High p-value 
dnLOF 
EG Ji et al. (current publication) 3915 0.0640 0.0286 0.1170 0.0715 0.1596 4.75E-07 
EG Dickinson et al. (ref. 14) 3326 0.0595 0.0253 0.1176 0.0730 0.1603 4.16E-07 
EG Georgi et al. (ref. 11) 2472 0.0494 0.0168 0.1254 0.0820 0.1671 7.82E-08 
human cell-EGs (ref. 20, 21, 22) 956 0.0079 0.0056 0.0193 -0.0269 0.0637 0.2118 
NEG 4919 0.0387 0.0309 0.0300 -0.0157 0.0774 0.1028 
Phenotypically uncharacterized 
genes 10823 0.0752 0.0533 0.0606 0.0143 0.1084 0.004257 
dnNSD 
EG Ji et al. (current publication) 3915 0.2061 0.1589 0.0794 0.0324 0.1274 3.41E-04 
EG Dickinson et al. (ref. 14) 3326 0.1875 0.1376 0.0892 0.0429 0.1353 8.13E-05 
EG Georgi et al. (ref. 11) 2472 0.1505 0.1050 0.0895 0.0435 0.1366 7.36E-05 
human cell-EGs (ref. 20, 21, 22) 956 0.0371 0.0365 0.0021 -0.0435 0.0499 0.4696 
NEG 4919 0.1611 0.1404 0.0374 -0.0100 0.0827 0.0691 
Phenotypically uncharacterized 
genes 10823 0.2471 0.2791 -0.0419 -0.0884 0.0044 0.9636 
inhRD 
EG Ji et al. (current publication) 3915 10.7428 10.6042 0.0420 -0.0041 0.0887 0.01688 
EG Dickinson et al. (ref. 14) 3326 9.3257 9.2358 0.0287 -0.0185 0.0757 0.04139 
EG Georgi et al. (ref. 11) 2472 7.0236 6.9163 0.0402 -0.0053 0.0867 0.02622 
human cell-EGs (ref. 20, 21, 22) 956 2.3745 2.3779 -0.0022 -0.0485 0.0435 0.5935 
NEG 4919 12.7816 12.8355 -0.0150 -0.0618 0.0308 0.7456 
Phenotypically uncharacterized 
genes 10823 20.3947 20.4559 -0.0133 -0.0592 0.0342 0.5404 
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Table 3.2 Difference in individual mutational burden between male and female 
probands. 
 
Variant 
Type 
Gene 
Set 
Female 
Proband 
Average 
Male 
Proband 
Average 
Effect 
Size p-value 
dnLoF 
EG 0.0862 0.0597 0.1042 0.0355 
NEG 0.0462 0.0357 0.0551 0.1782 
dnNSD 
EG 0.2400 0.1948 0.1014 0.0388 
NEG 0.2000 0.1596 0.0993 0.0742 
inhRD 
EG 11.0523 10.9633 0.0151 0.4711 
NEG 13.2677 13.0113 0.0360 0.5271 
Effect sizes were measured by Cohen's d, which is defined as the difference between both 
means divided by pooled standard deviation. P-values with statistical significance are in 
bold. 
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Table 3.3 Mutational burden analysis in ASD probands and unaffected siblings 
(dissected by the genders of proband-sibling pairs). 
Variant 
Type 
Gene 
Set 
Proband 
Gender 
Sibling 
Gender 
# 
Families 
Proband 
Average 
Sibling 
Average 
Effect 
Size p-value 
dnLoF 
EG 
All All 1781 0.0640 0.0286 0.1170 4.75×10-7 
Female Male 101 0.0891 0.0099 0.2588 0.0067 
Male Female 826 0.0593 0.0327 0.0893 0.0053 
Male Male 732 0.0615 0.0246 0.1228 0.0005 
Female Female 122 0.0902 0.0410 0.1461 0.0600 
NEG 
All All 1781 0.0387 0.0309 0.0300 0.1028 
Female Male 101 0.0396 0.0297 0.0374 0.3884 
Male Female 826 0.0412 0.0266 0.0558 0.0549 
Male Male 732 0.0369 0.0314 0.0213 0.2838 
Female Female 122 0.0328 0.0574 0.0818 0.8302 
dnNSD 
EG 
All All 1781 0.2061 0.1589 0.0794 0.0003 
Female Male 101 0.2178 0.1683 0.0724 0.2392 
Male Female 826 0.2094 0.1755 0.0552 0.0454 
Male Male 732 0.1885 0.1270 0.1136 0.0013 
Female Female 122 0.2787 0.2295 0.0725 0.2157 
NEG 
All All 1781 0.1611 0.1404 0.0374 0.0691 
Female Male 101 0.1881 0.1980 0.0155 0.5696 
Male Female 826 0.1465 0.1477 0.0022 0.5515 
Male Male 732 0.1667 0.1175 0.0904 0.0080 
Female Female 122 0.2049 0.1803 0.0379 0.3817 
inhRD 
EG 
All All 1781 10.7428 10.6042 0.0420 0.0169 
Female Male 101 10.3762 10.6436 0.0778 0.8260 
Male Female 826 10.8341 10.7034 0.0401 0.1120 
Male Male 732 10.5765 10.4372 0.0417 0.0449 
Female Female 122 11.4262 10.9016 0.1619 0.0430 
NEG 
All All 1781 12.7816 12.8355 0.0150 0.7456 
Female Male 101 12.5050 13.0792 0.1398 0.9143 
Male Female 826 12.8693 13.0182 0.0424 0.7802 
Male Male 732 12.6134 12.5546 0.0165 0.5576 
Female Female 122 13.4262 13.0820 0.0907 0.1327 
Effect sizes were measured by Cohen's d, which is defined as the difference between both 
means divided by the standard deviation of the paired differences. P-values were obtained 
from one-sided Wilcoxon signed rank test. 
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Table 3.4 Relationship between individual mutational burden and social 
responsiveness scale in ASD probands. 
 
 
 
Coefficients for Poisson regression are shown, which modeled the relationship between 
SRS total raw score and individual burden of all rare damaging mutations (including 
dnLOF, dnNSD and inhRD mutations). The p-value with statistical significance with 
positive estimated effects (p-value<0.05, estimate>0) is in bold. 
Group Gene Set Estimate Std. Error p-value 
2031 male 
probands 
EG (3915 genes) 0.001860 0.000381 1.08×10-6 
NEG (4919 genes) 0.000407 0.000324 0.209 
317 female 
probands 
EG (3915 genes) -0.001511 0.000877 0.085 
NEG (4919 genes) -0.003084 0.000682 6.04×10-6 
88 
 
Table 3.5 Relationship between individual mutational burden and IQ in ASD 
probands. 
 
Trait Gene Set Estimate Std. Error p-value 
Verbal IQ 
EG (3915 genes) -0.007279 0.000400 <2.2×10-16 
NEG (4919 genes) -0.005307 0.000383 <2.2×10-16 
Nonverbal IQ 
EG (3915 genes) -0.007172 0.000336 <2.2×10-16 
NEG (4919 genes) -0.004906 0.000320 <2.2×10-16 
Coefficients for Poisson regression are shown, which modeled the relationship between 
verbal/nonverbal IQ and individual burden of all rare damaging mutations (including 
dnLOF, dnNSD and inhRD mutations). 
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Table 3.6 The spatio-temporal expression specificity of essential genes in human brain. 
Tissue Stage p-value Genes 
# 
Genes 
# 
pASD 
OR 
pASD 
p-value 
pASD pASD list 
Cortex Early Mid Fetal 0.01 182 17 4.28 2.17E-06 
NFIB,TRIO,NFIA,ADNP,NUAK1,BCL11A,TBR1,TANC2,GRIN2B,KD
M4B,JUP,LDB1,KDM6B,DSCAM,SUV420H1,KDM5B,PBX1 
Striatum Early Mid Fetal 0.015 142 12 3.80 0.00018 
TRIO,DNMT3A,BCL11A,TANC2,RAI1,LDB1,FOXP1,RELN,KDM6B,
SUV420H1,KDM5B,PBX1 
Cortex Late Mid Fetal 1 109 9 3.68 0.0013 TRIO,PRPF39,TBR1,SYNGAP1,ANK2,JUP,PTMS,WNT9A,KDM6B 
Cerebell
um Early Fetal 3.77E-06 239 14 2.56 0.0021 
TRIO,FOXP1,ADNP,NR2F1,RFX7,BCL11A,SIX2,PAX5,JUP,DNMT3
A,KDM6B,SUV420H1,KDM5B,WNT7B 
Cortex Early Fetal 1.72E-16 348 18 2.25 0.0022 TBR1,CHD1,NFIA,PPM1D,TCF3,NFIB,NUAK1,RFX7,BCL11A,MIB1,SIX2,ERI1,TTK,POLD1,KDM6B,TANC2,KDM5B,PBX1 
Thalam
us Early Fetal 4.33E-08 271 13 2.06 0.0151 
CTNNB1,DNMT3A,WHSC1,RFX7,NR2F1,TCF7L2,TTK,JUP,SMARC
E1,RNF38,NUAK1,KDM5B,PBX1 
Amygda
la 
Late Mid 
Fetal 1 113 7 2.69 0.0200 TGM1,TRIO,ADNP,NR2F1,PRPF39,TBR1,WNT9A 
Hippoca
mpus Early Fetal 2.60E-28 375 16 1.83 0.0209 
CHD1,NFIB,NFIA,PPM1D,PTK7,TCF3,WHSC1,NR2F1,TBR1,MIB1,
TTK,POLD1,ILF2,ERI1,KDM5B,WNT7B 
Striatum Late Mid Fetal 1 131 7 2.30 0.0402 FOXP1,BCL11A,RAI1,ETV2,PTMS,KDM6B,DNMT3A 
Amygda
la 
Early Mid 
Fetal 1.13E-27 286 12 1.79 0.0463 
NFIB,DNMT3A,TCF3,WHSC1,RFX7,NR2F1,TBR1,TTK,POLD1,LDB
1,KDM6B,PBX1 
Cortex Neotal Early Infancy 1 58 4 3.01 0.0516 SYNGAP1,DSG3,SHANK2,PLCB1 
Cerebell
um Late Infancy 1 174 8 1.96 0.0614 TGM1,PRPF39,PPM1D,INTS6,ETV2,PTMS,RELN,RIMS1 
Cerebell
um Late Fetal 0.231 148 7 2.02 0.0685 NFIB,NFIA,PTK7,CTNNB1,RELN,OVOL1,WNT7B 
Hippoca
mpus 
Early Mid 
Fetal 2.61E-20 199 8 1.70 0.1110 NFIB,NFIA,ETV2,PTK7,TCF3,TBR1,TTK,KDM5B 
Amygda
la Early Fetal 1.05E-28 344 12 1.47 0.1320 
PPM1D,ADNP,TCF3,WHSC1,RFX7,NR2F1,TTK,POLD1,DNMT3A,S
MARCE1,KDM5B,ILF2 
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Cerebell
um 
Late Mid 
Fetal 5.54E-11 312 11 1.49 0.1376 
CHD1,NFIB,PTK7,TCF3,TGM1,TTK,EP400,RELN,OVOL1,DSCAM,
WNT7B 
Cerebell
um 
Middle Late 
Childhood 1 183 7 1.61 0.1564 TGM1,NFIA,PPM1D,SCN2A,RELN,ATP1A1,RIMS1 
Thalam
us 
Neotal Early 
Infancy 1 118 5 1.79 0.1582 ACHE,WNT9A,RIMS1,TCF7L2,SCN1A 
Thalam
us 
Early 
Childhood 1 58 3 2.21 0.1653 SCN1A,TCF7L2,RGMA 
Hippoca
mpus 
Late Mid 
Fetal 1 89 4 1.91 0.1692 PLVAP,NR3C2,WNT9A,NFIB 
Cerebell
um 
Early Mid 
Fetal 1.15E-11 271 9 1.39 0.2118 PLVAP,DNMT3A,PTK7,TCF3,JUP,RELN,WNT9A,LAMB1,WNT7B 
Cortex Young Adulthood 1 100 4 1.69 0.2235 PLCB1,SCN1A,TBR1,NUAK1 
Cortex Adolescence 1 73 3 1.73 0.2595 PLCB1,SCN1A,NUAK1 
Cerebell
um 
Young 
Adulthood 1 147 5 1.42 0.2840 TGM1,SCN2A,RELN,ATP1A1,RIMS1 
Thalam
us 
Early Mid 
Fetal 1 113 4 1.48 0.2925 NR2F1,WNT9A,TCF7L2,RGMA 
Cerebell
um 
Early 
Childhood 1 151 5 1.39 0.3028 TGM1,SCN2A,RELN,ATP1A1,RIMS1 
Cerebell
um Adolescence 1 158 5 1.32 0.3361 TGM1,SCN2A,RELN,ATP1A1,RIMS1 
Cortex Middle Late Childhood 1 50 2 1.68 0.3420 NUAK1,PLCB1 
Striatum Early Fetal 3.04E-40 441 12 1.13 0.3805 CHD1,PPM1D,TCF3,WHSC1,RFX7,ERI1,TTK,POLD1,DNMT3A,SMARCE1,ABL1,PBX1 
Amygda
la 
Middle Late 
Childhood 1 21 1 2.02 0.4023 FERMT1 
Hippoca
mpus 
Middle Late 
Childhood 1 57 2 1.47 0.4028 NR3C2,NCKAP1 
Thalam
us 
Young 
Adulthood 1 105 3 1.19 0.4687 SHANK3,TCF7L2,SCN1A 
Thalam Late Mid 1 109 3 1.14 0.4934 TGM1,WNT9A,TCF7L2 
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us Fetal 
Thalam
us Adolescence 1 113 3 1.10 0.5175 ACHE,TCF7L2,SCN1A 
Hippoca
mpus 
Early 
Childhood 1 73 2 1.14 0.5304 NR3C2,MYO1E 
Thalam
us 
Middle Late 
Childhood 1 116 3 1.07 0.5351 FERMT1,TCF7L2,SCN1A 
Striatum Late Fetal 7.64E-06 208 5 0.99 0.5685 TTK,POLD1,FERMT1,FOXP1,KDM6B 
Cerebell
um 
Neotal Early 
Infancy 1 122 3 1.02 0.5694 PTK7,RELN,ATP1A1 
Cortex Late Fetal 1 91 2 0.91 0.6502 JUP,TBR1 
Cortex Early Childhood 1 43 1 0.96 0.6516 GRIN2B 
Hippoca
mpus Adolescence 1 94 2 0.88 0.6677 NR3C2,SHANK3 
Hippoca
mpus Late Fetal 1 105 2 0.78 0.7256 PLVAP,TTK 
Thalam
us Late Fetal 1 114 2 0.72 0.7665 ACHE,TCF7L2 
Hippoca
mpus 
Neotal Early 
Infancy 1 60 1 0.68 0.7706 WNT7B 
Striatum Early Childhood 1 61 1 0.67 0.7761 PLCB1 
Thalam
us Late Infancy 1 62 1 0.66 0.7816 TCF7L2 
Amygda
la Late Fetal 1 119 2 0.69 0.7868 TBR1,ERI1 
Hippoca
mpus 
Young 
Adulthood 1 64 1 0.64 0.7920 NR3C2 
Striatum Middle Late Childhood 1 72 1 0.57 0.8292 FERMT1 
Striatum Late Infancy 1 86 1 0.47 0.8790 RPL12 
Striatum Young Adulthood 1 107 1 0.38 0.9278 MYO1E 
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Striatum Adolescence 1 136 1 0.30 0.9647 PLCB1 
Amygda
la 
Neotal Early 
Infancy 1 41 0 0.00 1  
Amygda
la 
Early 
Childhood 1 29 0 0.00 1  
Hippoca
mpus Late Infancy 1 72 0 0.00 1  
Amygda
la Adolescence 1 62 0 0.00 1  
Amygda
la Late Infancy 1 77 0 0.00 1  
Amygda
la 
Young 
Adulthood 1 52 0 0.00 1  
Cortex Late Infancy 1 41 0 0.00 1  
Striatum Neotal Early Infancy 1 95 0 0.00 1  
pASD, potential ASD genes (n=441); OR, odds ratio. P-values and odds ratios are from one-sided Fisher’s exact test s. 
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Table 3.7 Co-expression modules in the brain. 
 
Module #Gene Expression pattern Enrichment #EG #NEG 
Odds ratio 
(EG/NEG) 
p-value 
(EG/NEG) 
#Potential 
ASD genes 
Odds ratio 
(ASD genes) 
p-value 
(ASD genes) 
M01 1601 Early expressed EG-enriched 501 251 2.73 7.38*10-38 55 1.52 0.004 
M02 1150 Early expressed EG-enriched 367 208 2.34 2.80*10-22 53 2.13 2.58×10-6 
M03 1054 Mixed NEG-enriched 204 340 0.74 9.67*10-4 18 0.72 0.934 
M04 810 Late expressed NEG-enriched 122 326 0.45 3.19*10-14 19 1.00 0.529 
M05 781 Late expressed NEG-enriched 156 239 0.81 0.0491 24 1.32 0.122 
M06 702 Late expressed NEG-enriched 129 254 0.63 1.55*10-5 11 0.65 0.948 
M07 663 Early expressed EG-enriched 251 141 2.32 1.23*10-15 8 0.50 0.989 
M08 580 Early expressed EG-enriched 193 114 2.19 3.62*10-11 13 0.95 0.613 
M09 559 Late expressed NEG-enriched 104 206 0.62 9.26*10-5 16 1.23 0.246 
M10 503 Early expressed EG-enriched 126 114 1.40 0.0102 9 0.74 0.847 
M11 457 Late expressed NEG-enriched 79 178 0.55 7.33*10-6 9 0.83 0.753 
M12 420 Late expressed NEG-enriched 62 163 0.47 1.90*10-7 7 0.69 0.874 
M13 418 Late expressed NEG-enriched 97 193 0.62 1.46*10-4 7 0.69 0.877 
M14 370 Late expressed EG-enriched 81 58 1.77 0.00102 4 0.45 0.977 
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M15 368 Mixed EG-enriched 104 95 1.39 0.0251 5 0.57 0.934 
M16 347 Early expressed EG-enriched 106 90 1.49 0.00570 20 2.57 2.80×10-4 
M17 339 Early expressed EG-enriched 102 59 2.20 1.20*10-06 16 2.05 0.008 
M18 306 Late expressed 
 
66 61 1.37 0.0874 5 0.67 0.861 
M19 299 Late expressed NEG-enriched 31 118 0.32 1.81*10-9 2 0.28 0.994 
M20 296 Late expressed NEG-enriched 51 91 0.70 0.0498 5 0.72 0.823 
M21 291 Early expressed 
 
54 73 0.93 0.719 5 0.72 0.818 
M22 278 Early expressed EG-enriched 83 25 4.24 6.17*10-12 2 0.29 0.991 
M23 272 Late expressed NEG-enriched 41 84 0.61 0.0108 2 0.31 0.988 
M24 258 Early expressed 
 
51 49 1.31 0.189 11 1.84 0.047 
M25 244 Early expressed EG-enriched 86 49 2.23 6.66*10-6 11 1.98 0.031 
M26 239 Early expressed EG-enriched 79 18 5.61 8.28*10-14 4 0.70 0.821 
M27 213 Late expressed NEG-enriched 45 85 0.66 0.0261 6 1.19 0.399 
M28 197 Late expressed 
 
32 41 0.98 1 1 0.21 0.991 
M29 193 Late expressed NEG-enriched 33 69 0.60 0.0158 2 0.43 0.943 
M30 188 Late expressed NEG-enriched 11 43 0.32 2.92*10-4 3 0.69 0.808 
M31 187 Late expressed 
 
41 64 0.80 0.323 6 1.38 0.279 
M32 172 Late expressed NEG-enriched 24 60 0.50 0.00388 3 0.75 0.766 
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M33 170 Late expressed 
 
41 40 1.29 0.263 4 1.00 0.568 
M34 163 Mixed EG-enriched 48 22 2.76 5.06*10-5 2 0.51 0.904 
M35 151 Mixed NEG-enriched 21 48 0.55 0.0207 6 1.73 0.147 
M36 151 Late expressed 
 
22 44 0.63 0.0815 3 0.82 0.707 
M37 146 Early expressed EG-enriched 38 9 5.35 3.81*10-7 2 0.57 0.862 
M38 128 Late expressed NEG-enriched 17 63 0.34 2.11*10-5 4 1.36 0.347 
M39 115 Early expressed 
 
29 42 0.87 0.632 4 1.47 0.298 
M40 99 unknown 
 
4 13 0.39 0.0926 1 0.45 0.890 
M41 74 unknown NEG-enriched 4 16 0.31 0.0400 1 0.59 0.816 
P-values with statistical significance are in bold.  
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Table 3.8 Reactome pathways enriched in three EG-enriched modules implicated in ASD. 
Module Term Overlap p-value Adjusted p-value Genes 
M01 
Transcription 25/202 2.40*10-6 6.79*10-4 
GTF3C3;HDAC2;CCNT2;GTF3C4;RRN3;CSTF3;GTF2E
1;CLP1;PCF11;POLR2B;SNAPC3;CSTF1;RNGTT;TBP;
NCBP1;NCBP2;GTF2H3;NFIA;POLR3B;NFIB;POLR3C;
POLR1B;POLR1E;TFAM;TAF5 
Processing of Capped Intron-
Containing Pre-mRNA 22/144 4.34*10
-7 3.67*10-4 
NCBP1;NUP133;DHX9;NCBP2;CSTF3;CDC5L;HNRNP
U;PLRG1;YBX1;NUP160;EFTUD2;PRPF4;CLP1;HNRN
PH1;PCF11;POLR2B;NUP50;CSTF1;NUPL1;RAE1;SF3
B1;CTNNBL1 
Folding of actin by CCT/TriC 7/9 1.11*10-6 4.70*10-4 CCT3;CCT6A;CCT2;TCP1;CCT7;CCT5;CCT4 
mRNA Splicing 17/113 1.11*10-5 0.00188 
NCBP1;DHX9;NCBP2;CSTF3;CDC5L;HNRNPU;PLRG1
;YBX1;EFTUD2;PRPF4;CLP1;HNRNPH1;PCF11;POLR
2B;CSTF1;SF3B1;CTNNBL1 
HIV Infection 23/218 6.34*10-5 0.00589 
CCNT2;PSMD11;RNGTT;TBP;TSG101;NCBP1;NUP133
;NCBP2;XRCC5;HMGA1;NEDD4L;GTF2H3;GTF2E1;N
UP160;AP1G1;POLR2B;NUP50;PSMD2;TAF5;NUPL1;
PAK2;RAE1;KPNB1 
HIV Life Cycle 18/137 3.19*10-5 0.00451 
CCNT2;RNGTT;TBP;TSG101;NCBP1;NUP133;NCBP2;
XRCC5;HMGA1;NEDD4L;GTF2H3;GTF2E1;NUP160;P
OLR2B;NUP50;TAF5;NUPL1;RAE1 
snRNP Assembly 10/49 8.30*10-5 0.00589 NCBP1;NUP133;NCBP2;NUP50;TGS1;DDX20;NUPL1;RAE1;NUP160;WDR77 
Formation of tubulin folding 
intermediates by CCT/TriC 7/20 5.94*10
-5 0.00589 CCT3;CCT6A;CCT2;TCP1;CCT7;CCT5;CCT4 
Association of TriC/CCT with target 
proteins during biosynthesis 8/29 7.19*10
-5 0.00589 CCT3;CCT6A;CCT2;TCP1;XRN2;CCT7;CCT5;CCT4 
Regulation of cholesterol biosynthesis 
by SREBP (SREBF) 10/53 1.47*10
-4 0.00890 SQLE;SEC24B;GGPS1;NFYA;TGS1;CYP51A1;HMGCR;SEC24D;KPNB1;FDFT1 
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M02 
Chromatin organization 35/208 3.76*10-15 1.41*10-12 
PHF2;KDM5C;SMARCB1;TRRAP;EHMT2;EHMT1;CHD
4;ACTB;PHF21A;NSD1;SAP130;EP400;WDR5;EP300;B
RD8;WHSC1;MTA2;KDM6B;BRD1;CREBBP;KDM4B;S
MARCC2;KDM2B;SETDB1;SETD1B;USP22;D 
NMT3A;ARID1A;GATAD2A;HCFC1;SMARCA4;NCOR1;
KAT6B;KAT6A;RCOR1 
Processing of Capped Intron-
Containing Pre-mRNA 19/144 3.55*10
-7 8.87*10-5 
NUP214;SF3A1;SF3B2;SF3B3;NUP155;FUS;DDX23;SM
C1A;PRPF8;SRRM1;NUP93;PRPF6;U2AF2;NUP62;PO
LR2D;TPR;DHX38;NUP98;SNRNP200 
Transcription 18/202 1.02*10-4 0.00660 
GTF3C1;NFIX;POU2F1;EHMT2;CHD4;SSRP1;GATAD2
A;SRRM1;POLR3A;POLR1A;U2AF2;POLR2D;TCEB3;U
BTF;DHX38;MTA2;TAF4;TAF1 
PKMTs methylate histone lysines 7/29 8.03*10-5 0.00660 SETDB1;EHMT2;NSD1;SETD1B;WDR5;EHMT1;WHSC1 
Transport of Mature mRNA derived 
from an Intron-Containing Transcript 9/50 5.80*10
-5 0.00660 NUP214;NUP93;NUP155;U2AF2;NUP62;TPR;DHX38;NUP98;SRRM1 
HATs acetylate histones 13/105 4.91*10-5 0.00660 BRD1;CREBBP;TRRAP;USP22;ACTB;HCFC1;KAT6B;KAT6A;SAP130;EP400;WDR5;EP300;BRD8 
Transport of Mature Transcript to 
Cytoplasm 9/54 9.84*10-
5 0.00660 NUP214;NUP93;NUP155;U2AF2;NUP62;TPR;DHX38;NUP98;SRRM1 
mRNA Splicing 13/113 9.74*10-5 0.00660 SF3A1;SF3B2;SF3B3;FUS;DDX23;SMC1A;PRPF8;SRRM1;PRPF6;U2AF2;POLR2D;DHX38;SNRNP200 
Regulation of lipid metabolism by 
Peroxisome proliferator-activated 
receptor alpha (PPARalpha) 
13/114 1.06*10-4 0.00660 ABCA1;MED1;CREBBP;NCOA6;NRF1;MED26;SREBF2;MED12;MED14;MED24;NCOR1;SIN3A;EP300 
Transcriptional regulation of white 
adipocyte differentiation 11/78 6.57*10
-5 0.00660 MED12;MED1;CREBBP;MED14;MED24;NCOR1;NCOA6;EP300;LPL;MED26;SREBF2 
M16 
Axon guidance 11/327 2.24*10-4 0.0740 GSK3B;ARHGEF12;ROCK2;RASA1;KCNQ3;ANK2;ANK3;ARHGEF7;GRIN2B;MYH10;ITGA9 
Synthesis of PIPs at the early endosome 
membrane 3/13 3.84*10
-4 0.0740 INPP4A;PIKFYVE;PIK3C3 
CREB phosphorylation through the 
activation of Ras 3/27 2.54*10
-3 0.122 PDPK1;BRAF;GRIN2B 
Insulin receptor signalling cascade 5/92 0.00191 0.122 PDPK1;GRB10;PIK3C3;TSC1;MTOR 
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EPH-Ephrin signaling 5/94 0.00209 0.122 ROCK2;RASA1;ARHGEF7;GRIN2B;MYH10 
Sema4D induced cell migration and 
growth-cone collapse 3/24 0.00187 0.122 ARHGEF12;ROCK2;MYH10 
Interaction between L1 and Ankyrins 3/29 0.00306 0.131 KCNQ3;ANK2;ANK3 
Post NMDA receptor activation events 3/35 0.00501 0.143 PDPK1;BRAF;GRIN2B 
Signaling by Insulin receptor 5/116 0.00497 0.143 PDPK1;GRB10;PIK3C3;TSC1;MTOR 
PI3K Cascade 4/68 0.00423 0.143 PDPK1;PIK3C3;TSC1;MTOR 
CREB, cAMP response element binding protein; HATs, histone acetyltransferases; NMDA, N-methyl-D-aspartate; PKMTs, protein lysine methyltransferases; 
PIPs, phosphatidylinositol phosphates; PI3K, phosphoinositide 3-kinase; snRNP, small nuclear ribonucleo proteins; SREBP, sterol regulatory element-binding 
proteins; TriC/CCT, TCP1-ring complex or chaperonin containing TCP1. Adjusted P-values with statistical significance are in bold.   
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  Table 3.9 Priority list of 29 essential genes as strong ASD candidates. 
Gene Chr Start End Module 
TADA 
FDR q-
value 
# High-confidence 
ASD genes that 
are co-expressed 
Disease associations 
BIRC6 2 32357028 32618899 M02 0.47 15 - 
CHD1 5 98853985 98928957 M01 0.17 15 CHD8 has been previously associated with autism 
CUL1 7 148697914 148801036 M01 0.49 12 - 
DHX29 5 55256245 55307722 M01 0.40 17 - 
DVL3 3 184155388 184173610 M02 0.33 10 Robinow syndrome-3, characterized by skeletal abnormalities 
EP300 22 41091786 41180077 M02 0.45 13 
Rubinstein-Taybi syndrome, characterized by short stature, 
moderate to severe learning difficulties, distinctive facial 
features, and broad thumbs and first toes. 
EP400 12 131949920 132081102 M02 0.43 9 - 
FBXO11 2 47789316 47905793 M01 0.15 17 
Associated with chronic otitis media with effusion and 
recurrent otitis media, a hearing loss disorder, and the ENU 
knockout of the homologous mouse gene results in the deaf 
mouse mutant Jeff (Jf) 
KDM4B 19 4969113 5153595 M02 0.30 14 - 
LDB1 10 102107560 102120453 M02 0.42 14 - 
LTN1 21 28928144 28992956 M16 0.37 3 - 
MORC3 21 36320189 36386148 M01 0.50 10 - 
MYH10 17 8474205 8630761 M16 0.13 3 
Essential for normal spine morphology and dynamics. 
Pharmacologic or genetic inhibition of Myh10 altered 
protrusive motility of spines, destabilized their mushroom-
head morphology, and impaired excitatory synaptic 
transmission. 
NFIB 9 14081843 14398983 M01 0.45 15 - 
PBX1 1 164555584 164899296 M01 0.46 16 - 
100 
 
PHF21A 11 45929323 46121178 M02 0.48 11 - 
RFX7 15 56087280 56243266 M01 0.25 17 - 
RNF38 9 36336396 36487548 M01 0.41 18 - 
SMARCE1 17 40624962 40648508 M01 0.41 12 Meningiomas (brain and spinal cord tumors) 
SNW1 14 77717599 77761207 M01 0.44 12 - 
STXBP5 6 147204425 147390476 M16 0.37 2 - 
SUFU 10 102503987 102633535 M02 0.47 14 Familial Meningioma, Medulloblastoma 
TAF4 20 61953469 62065810 M02 0.30 10 
Interference of transcription by the binding of TAF4 with 
expanded polyQ stretches is involved in the pathogenetic 
mechanisms underlying neurodegeneration. 
TANC2 17 63009556 63427699 M02 0.32 14 - 
TNPO3 7 128954180 129055173 M01 0.19 17 Mutations found in patients with muscular dystrophy 
UTP6 17 31860899 31901765 M01 0.19 12 - 
VCP 9 35056064 35073249 M02 0.49 9 
Inclusion Body Myopathy with Paget Disease of Bone and 
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, 
Charcot-Marie-Tooth Disease Type 2Y 
WHSC1 4 1871424 1982207 M02 0.27 13 Located in the Wolf-Hirschhorn syndrome (WHS) critical region 
YTHDC1 4 68310387 68350089 M01 0.48 11 - 
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Supplementary data 
Supplementary data 3.1 List of de novo variants in EGs and NEGs in subjects from 
the Simons Simplex Collection. 
Supplementary data 3.2 List of inherited variants in EGs and NEGs in subjects 
from the Simons Simplex Collection. 
Supplementary data 3.3 Individual mutational burden, essentiality burden score, 
polygenic risk score and rare deletion burden of subjects from the Simons Simplex 
Collection. 
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CHAPTER 4: Essentiality burden score and its application to 
understanding the genetic architecture of ASD 
Introduction 
A current model for understanding the genetic etiology of ASD involves the cumulative 
effects of both common and rare variants including both SNVs and CNVs (de la Torre-
Ubieta et al., 2016). A few polygenic methods for investigating the genetic architecture of 
complex disorders have been proposed (Wray et al., 2014). Polygenic risk score (PRS) 
aims to provide insight into the genetic architecture captured by common SNVs from 
GWAS (International Schizophrenia et al., 2009). Specifically, PRS for each individual is 
calculated as the number of risk alleles weighted by their effect sizes estimated from a 
discovery GWAS (Wray et al., 2014). Since PRS summarizes the individual-level genetic 
effects among a group of SNVs that do not individually reach genome-wide significance, 
it can be used to construct disease risk prediction models (Dudbridge, 2013).  PRS 
analyses have been applied in a few recent ASD studies. For example, The Autism 
Genome Project Consortium performed a two-stage GWAS in a total of 2,705 ASD 
familes (including 1,404 families in Stage 1 and 1,301 families in Stage 2) (Anney et al., 
2012; Anney et al., 2010). Anney et al. found that PRS based on summary statistics from 
Stage 1 GWAS is a significant predictor of Stage 2 case-control status (Anney et al., 
2012), which validated the collective contribution of common variants to ASD risk. 
Furthermore, based on ASD GWAS on ~5,000 cases and ~5,000 controls performed by 
Psychiatric Genomics Consortium (Smoller et al., 2013),  Weiner et al. compared the 
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PRS between ~6,400 ASD children and their parents and confirmed that common 
polygenic variants contribute to ASD risk in addition to strong acting de novo events 
(Weiner et al., 2016). Recent studies on CNVs implicated their significant role in the 
genetic architecture of ASD (Bucan et al., 2009; Glessner et al., 2009; Griswold et al., 
2012; Itsara et al., 2010; Levy et al., 2011; Malhotra and Sebat, 2012; Marshall et al., 
2008; Pinto et al., 2010b; Sanders et al., 2011; Sanders et al., 2015; Sebat et al., 2007; 
Szatmari et al., 2007). Global CNV load, which is defined as the total number of base 
pairs covered by CNVs per individual, had been suggested to predispose to autism 
(Girirajan et al., 2013). While PRS captures the cumulative effect of common variants in 
both EGs and NEGs, based on an increased burden of inherited, rare and damaging 
mutations in EGs in ASD probands compared to their unaffected siblings (Ji et al., 2016), 
I suggested that the burden of rare variants in EGs could be an additional polygenic 
predictor of individual ASD risk.  
In the previous chapter, I defined the individual mutation burden as i) the number of 
alternative alleles below a defined threshold of minor allele frequency (MAF<0.01) and 
ii) above a defined threshold of the Combined Annotation-Dependent Depletion (CADD) 
score that measures variant-level deleteriousness by integrating diverse genome 
annotations (CADD phred-scale>10) (Ji et al., 2016). However, the individual mutation 
burden did not take into account the magnitude of damaging effects for each variant, and 
thus may not be an optimal predictor of individual ASD risk. To evaluate the optimal 
predictor of individual’s ASD risk and to improve the power to differentiate unaffected 
individuals from ASD subjects with different degrees of social and cognitive impairment, 
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I developed an Essentiality Burden Score (EBS). The EBS is defined as the weighted sum 
of coding variants in essential genes per individual. The weights are based on measures 
of variant-level deleteriousness (as a proxy for pathogenicity), minor allele frequency 
(MAF), and gene-level intolerance scores (Aggarwala and Voight, 2016; Lek et al., 2016; 
Petrovski et al., 2013) . The optimized weighing scheme for EBS can be found by 
maximizing the difference in EBS between ASD patients and unaffected siblings in the 
discovery dataset (1,781 ASD proband-siblings pairs from Simons Simplex Collection, 
Table 4.1).  
Using weights learned in the discovery phase, I calculated EBS for individuals and 
families in the target dataset (688 trio families in the ASC exome sequencing dataset, 
Table 4.1) for validation of the association of EBS to ASD using parent-child 
relationships. To demonstrate how EBS can facilitate a deeper understanding of the 
genetic architecture of ASD, I compared EBS, PRS and CNV load and evaluate the 
power of these polygenic methods in predicting ASD disease status. Moreover, I 
investigated the potential interplay between EBS and rare variants in high-penetrant ASD 
risk genes such as NRXN1. 
Results 
Optimization of the essentiality burden score (EBS) 
I evaluated the performance of EBS under different weighing schemes in the discovery 
sample (1,781 ASD proband-sibling pairs from SSC). The contributions of CADD score, 
MAF [non-Finnish European population in ExAc, (Lek et al., 2016)] and intolerance 
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scores for the performance of EBS were assessed by four metrics: P values and effect 
sizes from one-sided Wilcoxon signed rank test for higher EBS in ASD probands; 
percentage of proband-sibling pairs in which probands have higher EBS (accuracy); area 
under ROC curve (AUC) for the performance of EBS in discriminating between ASD 
probands and unaffected siblings (Figure 4.2). I observed that both intolerance scores and 
CADD score contribute to improved performance of EBS, and that MAF contribute 
minimally to the performance of EBS. The product of the weights from CADD scores 
and intolerance scores provides the best performance for EBS (Figure 4.2, Table 4.3, 
Materials and Methods). Under this model, the P value for elevated EBS in 1,781 ASD 
probands compared to their unaffected siblings is 2.26 ×10-5, which is a substantial 
improvement compared with the individual mutational burden described in chapter 3 (P 
value =0.0021) (Ji et al., 2016). It is notable that although the effect of increased EBS in 
ASD probands is statistically significant, the predicting power of EBS in differentiating 
between ASD probands and unaffected siblings is modest (accuracy=0.542, 
AUC=0.520).  
Regression analysis of the effect of EBS on quantitative traits of ASD probands 
Next I investigated the relationship between EBS and quantitative traits available for 
~2,500 ASD probands in SSC (Supplementary data 3.3). I confirmed the significant 
effect of EBS on Social Responsiveness Scale (SRS) in male probands (P value=2.32 
×10-6; Poisson regression) but not in female probands (P value =0.085; Poisson 
regression), as well as the effect of EBS on verbal and non-verbal IQ (P value <2 ×10-16 
for both verbal and non-verbal IQ; Poisson regression). Moreover, increased EBS in 
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probands is associated with parents’ age at their births, with a stronger effect on the age 
of fathers (P value =0.00414; Poisson regression) than mothers (P value =0.0109; Poisson 
regression). When EBS was dissected by the contributions of de novo or inherited 
mutations separately, both de novo and inherited mutations contribute to this effect on the 
age of fathers (P value =1.11 ×10-8   for de novo, P value = 0.0384 for inherited; Poisson 
regression) and mothers (P value = 0.00849 for de novo, P value = 0.0283 for inherited; 
Poisson regression). EBS in the probands is not associated with probands’ head 
circumference (P value = 0.695; Poisson regression) and number of miscarriages in the 
family (P value = 0.40; Poisson regression). 
The extension of polygenic transmission disequilibrium test to EBS 
It is expected that a child inherits half of the variants from each of their parents, thus the 
child’s expected EBS is the average EBS of their parents. However, in a collection of trio 
families in which the children are affected with a trait or disease (such as ASD), the 
association between EBS and the trait introduces deviation of children’s EBS from the 
expected value. To further validate the association of EBS to ASD using parent-child 
relationships in the ASC exome sequencing dataset, I extended the polygenic 
transmission disequilibrium test (Weiner et al., 2016) to EBS. The extension of the 
transmission disequilibrium test to EBS is equivalent to testing the difference between 
affected children’s EBS and the means of paternal and maternal EBS. Using exome 
sequencing data of 688 ASD trio families from Autism Sequencing Collaboration, I 
compared the EBS of ASD children with their unaffected parents (Figure 4.3, 
Supplementary data 4.1). I found that the EBS of ASD children were greater than the 
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paternal EBS (P value =0.0136; paired two-sample t-test, one-sided), but not the maternal 
EBS (P value = 0.6632; paired two-sample t-test, one-sided). In addition, the maternal 
EBS were marginally greater than paternal EBS in these families (P value = 0.0524; 
paired two-sample t-test, one-sided). I did not detect significantly increased EBS of ASD 
children compared to both parents (P value = 0.3675; one-sided two-sample t-test). I 
found that the ASD children’s EBS is marginally increased compared to the means of 
paternal and maternal EBS (P value = 0.054, paired two-sample t-test, one-sided), further 
supporting the association between increased burden of deleterious variants in EGs and 
ASD.  
The independent contributions of EBS, polygenic risk score (PRS) and rare deletion 
burden (RDB) for ASD risk prediction 
The cumulative effect of rare variants in EGs is not the only factor that determines ASD 
disease status, as polygenic effect of common variants, burden of copy number variations 
(CNVs) and rare variants with high penetrance can be additional genetic factors that 
predict ASD risk. To test this hypothesis, I took advantage of available exome 
sequencing and SNP genotyping data of 701 SSC families for which both EBS and PRS 
could be estimated. The EBS of the 701 SSC proband-sibling pairs were calculated using 
called variants in their exomes. Using the SNP genotyping data of 701 SSC proband-
sibling pairs, I calculated their PRS based on the summary statistics in a GWAS on 5,305 
ASD cases and 5,305 psuedocontrols performed by the Psychiatry Genomics Consortium 
(Smoller et al., 2013). A low negative correlation was observed between the EBS and 
PRS of 701 SSC ASD probands (Pearson correlation = -0.318, Figure 4.4), suggesting 
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that the effects of EBS and PRS were independent to each other. Based on a list of rare 
CNVs in ~2,500 SSC ASD families (Table 4.2) (Sanders et al., 2015), I calculated the 
rare deletion burden (RDB) of these individuals. RDB was not correlated with either EBS 
(Pearson correlation=0.042) or PRS (Pearson correlation=-0.056). To evaluate and 
compare the performance of EBS, PRS and RDB in predicting ASD affected status, I 
performed logistic regression using the EBS, PRS and RDB of 670 proband-sibling pairs 
as independent variables. The performance of regression models based combinations of 
the three metrics considered (EBS, PRS, and RDB) was evaluated by area under ROC 
curve (AUC) (Figure 4.5). The performance of EBS and that of RDB alone was modest 
(EBS: AUC=0.514; RDB: AUC=0.515). The performance of PRS is inflated (PRS: 
AUC=0.806), probably because the ASD GWAS from PGC included overlapping 
subjects from the SSC cohorts. Regardless of the inflated performance of PRS, EBS and 
RDB still improved the prediction power when incorporated together with PRS 
(EBS+PRS: AUC=0.831; RDB+PRS: AUC=0.811). The best performance was achieved 
when the regression model included all of the three metrics (EBS+RDB+PRS: 
AUC=0.833) (Figure 4.5, Table 4.4). The regression coefficients of PRS, EBS and RDB 
were all significant (PRS: P value <2 ×10-16; EBS: P value =1.28 ×10-12; RDB: P value 
=0.0131). The effect of EBS on ASD affected status was stronger than that of RDB 
(EBS: coefficient=0.518; RDB: coefficient=0.333). Overall, the results suggest that EBS, 
PRS and RDB capture different aspects of the genomic landscape of ASD and provide 
more power to predict ASD risk when combined and considered together. 
The interplay between EBS and NRXN1 variants with a major effect 
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Next I hypothesized that high-penetrant alleles in ASD risk genes may play an important 
role in some ASD individuals with lower EBS. NRXN1 is a synaptic cell-adhesion 
molecule and a component of the trans-synaptic complex, which is crucial for normal 
synapse formation and function. NRXN1 is also an unpublished EG (personal 
communication with Mark V. Fuccillo) that is significantly associated with ASD [TADA 
FDR=2.31 ×10-7, (Sanders et al., 2015)]. To investigate the potential interplay between 
rare variants in NRXN1 and EBS, I compiled a list of SSC families with rare CNVs and 
SNVs in NRXN1 (Figure 4.6). Firstly, I extracted 7 ASD families from SSC with rare 
exonic deletions in NRXN1 in at least one child, among which 6 are quartet families 
(Table 4.5). All of these 6 rare exonic deletions in NRXN1 were in probands (4 inherited 
and 2 de novo) and none was present in siblings only, indicating that these deletions 
could have strong effects and lead to ASD. Among the 7 probands with rare exonic 
deletions in NRXN1, 5 had lower EBS compared to their unaffected siblings. Secondly, I 
extracted 19 ASD quartet families from 1,781 SSC families in which rare functional 
mutations in NRXN1 were present in at least one child (Figure 4.6, Table 4.6). There were 
14 unique heterozygous mutations in NRXN1 in these 19 families (13 inherited and 1 de 
novo). With the assumption that NRXN1 mutations present in probands have stronger 
penetrance than those mutations only observed in unaffected siblings, I found that ASD 
probands with high-penetrance NRXN1 mutations are more likely to have lower EBS 
compared to their siblings (odds ratio=11.25, P value=0.0495; one-sided Fisher’s exact 
test) (Table 4.7).  These findings suggest that in some ASD patients, alleles in high-
penetrance ASD risk genes such as NRXN1 play an important role in the development of 
ASD, regardless of their lower mutational burden in EGs. 
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Discussion 
I developed the essentiality burden score (EBS) by giving weights to different variants 
according to their functional impact, which provides greater power to separate ASD 
probands from their unaffected siblings. I validated the effectiveness of EBS in an 
independent cohort (ASC) by extending the polygenic transmission disequilibrium test to 
EBS and showed that the EBS of ASD probands tends to be higher than the average EBS 
of their parents. I demonstrated the independent contributions of EBS, polygenic risk 
score (PRS) and rare deletion burden (RDB) for ASD risk prediction. Finally, I observed 
a potential interplay between EBS and NRXN1 variants with a major effect in ASD 
probands from Simons Simplex Collection. 
Since the era of genome-wide association studies (GWAS), the large proportion of the 
heritability of complex disorders such as ASD unexplained by GWAS, i.e. the “missing 
heritability” (Manolio et al., 2009; McCarthy et al., 2008), remains as a key question to 
be answered. With the advancement of next generation sequencing technology, many 
recent ASD studies have been successful in identifying many more ASD candidate genes 
by focusing on rare and de novo variants with a large functional impact (Iossifov et al., 
2014; Iossifov et al., 2012; Levy et al., 2011; Sanders et al., 2011; Sanders et al., 2012). 
Besides common variants in GWAS or rare variants with large genetic effect, my study 
focused on an important but less explored territory: low-frequency or rare variants with 
small to intermediate effect in EGs (Figure 4.7). The EBS captures the cumulative effect 
of a large number of rare deleterious variants in EGs. I found significantly elevated EBS 
in ASD probands and an independent contribution of EBS to ASD risk prediction, which 
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suggests that EBS analysis, along with PRS analysis that captures cumulative effect of 
common variants, is useful in identifying the “still-missing” heritability of ASD and thus 
important for a full understanding of the genetic landscape of ASD. Moreover, my results 
on elevated EBS in unaffected mothers compared to unaffected fathers in ASD trio 
families from the ASC cohort further support the “female protective model” in ASD, for 
which several studies have gathered reinforcing genetic evidence showing a higher 
burden of de novo loss-of function mutations (Iossifov et al., 2012) and CNVs 
(Jacquemont et al., 2014; Levy et al., 2011; Sanders et al., 2011; Sanders et al., 2015) in 
female ASD probands.  
It is not surprising that the predictive power of EBS alone on ASD risk is only moderate. 
Firstly, due to the complexity of the genomic architecture of ASD (de la Torre-Ubieta et 
al., 2016), we may expect that it is not a single genetic predictor but the joint contribution 
of a broad spectrum of genetic variants (Figure 4.7) that determines the genetic risk of 
ASD. This notion is supported by my results that i) the performance of ASD predicting 
models including all three genetic predictors (i.e. EBS, PRS and RDB) is superior to the 
models with only a single predictor and ii) high-penetrant NRXN1  mutations are 
associated with lower EBS in ASD probands. Secondly, for complex genetic disorders we 
may expect an influence of environmental factors, and therefore the predictive value of a 
single genetic risk factor is limited (Wray et al., 2014; Wray et al., 2010). Other identified 
non-genetic factors in ASD such as parental age, prenatal stress or infection, maternal 
Zn2+-deficiency and maternal exposure of toxins (Grabrucker, 2012), should also be 
taken into consideration in order to increase the predictive ability of genetic predictors 
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(Wray et al., 2014). Thirdly, there are still limitations in the current model for EBS, 
which has not taken into consideration variants in the X chromosome (that harbors 89 
EGs) and non-coding variants involved in regulating the expression of EGs. Finally, it is 
expected that EBS will achieve a better predictive value for ASD risk as the catalog of 
EGs continues to grow. 
Materials and Methods 
ASC exome sequencing data 
Exome sequence reads of 3,417 individuals in ARRA Autism Sequencing Collaboration 
(ASC) were downloaded from dbGaP (https://www.ncbi.nlm.nih.gov/gap; dbGaP Study 
Accession: phs000298.v1.p1). The reads were aligned to GRCh37/hg19 human genome 
with Burrows-Wheeler Aligner (BWA) 0.7.10 (Li and Durbin, 2009). Variant calling was 
performed with the Genome Analysis Toolkit (GATK) (3.2.2) with default protocols 
(McKenna et al., 2010). Variant filters include i) passed the GATK variant quality score 
recalibration (VQSR) filter, ii) call rate>=90% and c) Hardy Weinberg equilibrium P 
value >1× 10-6. Genotype filters include i) read depth (DP) >=8 and ii) genotype quality 
(GQ) >=20. The final variant call set included 934,511 variants with an average call rate 
of 99.2% and a transition / transversion ratio of 2.75. From the 3,417 individuals, I 
extracted 688 trio families with two unaffected parents and a child affected with ASD.  
SSC SNP genotyping data 
I obtained Illumina 1M SNP genotyping data of 4,753 individuals (1,223 probands and 
3,530 unaffected family members) in SSC. Invariant markers, duplicated variants, non-
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autosomal variants and variants with call rate <90% and Hardy Weinberg equilibrium P 
value < 1×10-7 were removed.  The final variant call set included 886,001 variants with 
an average call rate of 99.96%. The chromosomal positions of the variants were lifted 
over from hg18 to hg19 using the LiftOver tool from UCSC genome browser 
(https://genome.ucsc.edu). SNP array data were available for 701 SSC proband-sibling 
pairs among the 1,781 quartet families with exome sequencing data. 
Definition and optimization of the essentiality burden score (EBS) 
To calculate the EBS, suppose there are n functional variants (loss-of-function or 
missense) in a whole exome sequence or whole genome sequence dataset, Iij  indicates 
whether variant j exists in individual i. The EBS for individual i is defined as the 
weighted sum of the number of risk alleles in an individual:  
𝐸𝐸𝐸𝑖 = ��𝑊𝑗𝐼𝑖𝑗�𝑛
𝑗=1
 
For each functional variant, the weighing metric (W) combines evidence from i) minor 
allele frequency (MAF) in ExAC (European ancestry) (Lek et al., 2016), ii) variant-level 
deleteriousness quantified by CADD score (Kircher et al., 2014) and iii) gene-level 
intolerance scores including Residual Variation Intolerance Score (RVIS) (Petrovski et 
al., 2013), the probability of being loss-of-function intolerant (pLI) (Dickinson et al., 
2016)and genic intolerance based on sequence context (Aggarwala’s score) (Aggarwala 
and Voight, 2016) . 
WCADD = CADD phred-scale score  
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WMAF = [Beta (MAF; 1,25)]2 (Wu et al., 2011) 
Wintolerance =100-(RVIS percentile+pLI percentile+Aggarwala percentile)/3 
W= (WCADD*a1+ WMAF*a2)*Wintolerance^a3 
The objective of optimization was to learn the weights (a1, a2 and a3), using the discovery 
dataset, that maximally differentiates ASD cases from family controls. To achieve this, I 
used annotated variants in the discovery sample [1,781 ASD quartet families from SSC, 
specifically, variants reported in (Iossifov et al., 2014) and (Krumm et al., 2015)], to 
identify a combination of weighing metrics by maximizing the performance of EBS in 
differentiating between ASD probands and unaffected siblings. The performance of EBS 
were assessed by four metrics: P values and effect sizes from one-sided Wilcoxon signed 
rank test for higher EBS in ASD probands; percentage of proband-sibling pairs in which 
probands have higher EBS (accuracy); area under ROC curve (AUC) for the performance 
of EBS in discriminating between ASD probands and unaffected siblings.  
Calculation of ASD polygenic risk score (PRS) 
I downloaded GWAS results of a meta-analysis of 5,305 ASD-diagnosed cases and 5,305 
psuedocontrols constructed from untransmitted parental chromosome performed by the 
Psychiatric Genomics Consortium (Robinson et al., 2016). Using PRSice 1.25 (Euesden 
et al., 2015), I calculated the PRS of 701 SSC proband-sibling pairs at a P value threshold 
of 0.5, at which 1,223 probands were maximally differentiated from 3,530 unaffected 
family members (Figure 4.1). 
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Calculation of rare deletion burden (RDB) 
I acquired a list of rare CNVs (with population frequency <= 0.1%) predicted from 
Illumina Omni2.5 SNP genotyping data of 2,591 SSC ASD families (Table 4.2) (Sanders 
et al., 2015). The rare deletion burden (RDB) was defined as the total number of base 
pairs covered by rare deletions across an individual genome (Girirajan et al., 2013). 
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Figures 
 
Figure 4.1 PRS model fit across multiple GWAS P-value thresholds. The figure was 
generated by PRSice 1.25. For each GWAS p-value threshold (x-axis), a regression was 
performed to test the association between the PRS and ASD affected status of 1,223 SSC 
probands and 3,530 unaffected family members. The R2 and p-value for each regression 
model is shown. 
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Figure 4.2 Optimization of parameters for EBS. Performance of EBS in the discovery 
sample (1,781 ASD proband-sibling pairs from SSC) was evaluated with four metrics: (A) 
p-values (B) effect sizes from one-sided Wilcoxon signed rank test for higher EBS in 
ASD probands, (C) percentage of proband-sibling pairs in which probands have higher 
EBS, (D) area under ROC curve for the performance of EBS in discriminating between 
ASD probands and unaffected siblings.  
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Figure 4.3 Essentiality burden scores in ASD trio families. The boxplots indicate the 
distribution of essentiality burden score (EBS) of ASD children, mothers and fathers in 
685 trio families from ARRA Autism Sequencing Collaboration. “Mean” stands for the 
mean of paternal and maternal EBS.  One-sided paired two-sample t-tests for increased 
EBS in ASD children (top three p-values) and for increased EBS in mothers (bottom p-
value) were performed. *p-value<0.05. 
119 
 
 
Figure 4.4 The EBS and PRS of 701 ASD probands. The Pearson correlation between 
EBS and PRS is shown. 
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Figure 4.5 Performance of ASD prediction models. Multivariate logistic regression 
was performed to predict the affected status of 670 proband-sibling pairs. Combinations 
of three individual-level metrics [i.e. essentiality burden score (EBS), rare deletion 
burden (RDB), and polygenic risk score (PRS)] were used as independent variables in the 
regression models. The area under ROC curve for each of the six regression models is 
shown.  
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Figure 4.6 Rare exonic deletions and SNVs in NRXN1 in SSC. UCSC Genome 
Browser (http://genome.ucsc.edu/) view of 7 families with rare exonic deletions (long red 
bars) and 19 families with rare exonic SNVs (short red bars) in NRXN1 with SSC family 
ID is shown.  
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Figure 4.7 Spectrum of complex disease risk variants by allele frequency and effect 
size. This figure is from ref (Manolio et al., 2009), which is adapted from ref (McCarthy 
et al., 2008). 
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Tables 
Table 4.1 Datasets involved in Chapter 4. 
Cohort Type Platform Sample size Source 
SSC 
Rare variants (from 
whole exome 
sequencing) 
Illumina 
HiSeq 2000 
2,368 trio and 
quartet families 
Iossifov et al. 
2014; Krumm et al. 
2015 
SSC SNP genotyping Illumina 1M 
701 quartet 
families SSC 
SSC Rare CNVs 
Illumina 1M 
and Omni2.5 
2,591 trio and 
quartet families Sanders et al. 2015 
ASC 
Whole exome 
sequencing 
Illumina 
HiSeq 2000 
688 trio 
families ASC (dbGaP) 
The intersection between 2,369 families with rare variants and 2,591 families with rare 
CNVs are 2,181. 701 families with SNP genotyping data are a subset of 2,368 families 
with rare variants. 
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Table 4.2 Statistics of rare CNVs in 2,591 SSC ASD families. 
 Deletion Duplication 
 Exonic/Splicing Intronic/UTR Intergenic Exonic/Splicing Intronic/UTR Intergenic 
Both 173 15 184 504 0 65 
EG 1379 1874 1271 1031 400 336 
NEG 2144 2788 1611 1496 579 420 
Unknown 8231 6518 10866 4747 1390 3226 
Total 11927 11195 13932 7778 2369 4047 
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Table 4.3 The performances of different models of essentiality burden score. 
Model P Effect Size Accuracy AUC a1 a2 a3 
Burden 0.0021 0.0901 0.5376 0.5126 . . . 
MAF 0.0013 0.0884 0.5368 0.5129 0 1 0 
CADD 0.0012 0.0889 0.5298 0.5139 10 0 0 
MAF+CADD 0.0009 0.0906 0.5368 0.5129 10 1 0 
Intol 7.15E-05 0.1088 0.5379 0.5198 . . . 
MAF*Intol 7.41E-05 0.1086 0.5385 0.5198 0 1 1 
CADD*Intol 4.52E-05 0.1118 0.5418 0.5196 10 0 1 
(MAF+CADD)*Intol 5.31E-05 0.1108 0.5390 0.5187 10 1 1 
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Table 4.4 Regression analysis to predict ASD affected status. 
 
Estimate Std. Error Z value p-value 
EBS 0.51791 0.07298 7.096 1.28 ×10-12 * 
RDB 0.33346 0.13444 2.480 0.0131 * 
PRS 1.72517 0.09491 18.176 < 2 ×10-16 * 
Intercept 0.08912 0.06945 1.283 0.199 
Logistic regression was performed for the essentiality burden score (EBS), rare deletion 
burden (RDB), and polygenic risk score (PRS) of 670 proband-sibling pairs from SSC. * 
p-value <0.05. 
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Table 4.5 ASD families from SSC with rare exonic deletions in NRXN1. 
Family Chr Start Stop Inheritance EBS proband EBS sibling EBS difference 
12119 2 50831734 50873107 de novo 15598.29 NA NA 
12786 2 51158351 51661515 mother-both 24412.65 33687.31 -9274.67 
13580 2 51247294 51311532 de novo 23413.55 18604.00 4809.55 
13609 2 51236179 51332477 father-pro 459.63 1132.83 -673.20 
13718 2 51087308 51161424 mother-pro 10865.98 17306.43 -6440.45 
13962 2 50790714 51256013 de novo 8644.48 13599.03 -4954.55 
14443 2 51149414 51255832 father-both 1798.76 1808.08 -9.32 
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Table 4.6 ASD families from SSC with rare/damaging SNVs or indels in NRXN1. 
Family Chr Start Stop Ref Alt Inherit-ance 
EBS 
proband 
EBS 
sibling 
EBS 
difference 
13465 2 50280493 50280493 G - mo-pro 11078.04 19319.46 -8241.42 
12115 2 50282085 50282085 - T fa-sib 8444.06 7978.35 465.71 
12989 2 51253590 51253590 G A fa-both 18550.44 14013.83 4536.62 
12501 2 50724605 50724605 A T de novo 14371.08 14798.24 -427.15 
12032 2 50724817 50724817 G A mo-pro 23199.61 23704.83 -505.22 
14241 2 50724817 50724817 G A fa-pro 18231.69 15067.18 3164.52 
14629 2 50724817 50724817 G A fa-sib 15127.46 22051.87 -6924.41 
12953 2 50724817 50724817 G A fa-pro 13878.68 16416.71 -2538.03 
13852 2 50724817 50724817 G A mo-sib 729.02 0 729.02 
13998 2 51255218 51255218 C T fa-both 36937.25 36923.27 13.98 
13931 2 50149233 50149233 C T mo-pro 13900.33 16532.63 -2632.3 
11030 2 50780151 50780151 T A mo-sib 13235.1 4629.40 8605.70 
14523 2 50779938 50779938 G T mo-sib 24330.59 22213.44 2117.15 
12484 2 50149314 50149314 G A mo-pro 19311.12 16490.36 2820.7 
13944 2 50779784 50779784 A C mo-sib 27655.17 26322.5 1332.67 
12950 2 50280477 50280477 T A mo-both 24713.45 27057.88 -2344.44 
12695 2 50699532 50699532 G C mo-both 19295.37 23723.99 -4428.62 
14225 2 51253608 51253608 C T fa-both 22945.78 24235.69 -1289.91 
11721 2 51253608 51253608 C T fa-pro 21189.56 21563.92 -374.36 
All listed variants have CADD score>10. mo, mother; fa, father. 
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Table 4.7 Relationship between mutations in NRXN1 and EBS in ASD quartet 
families. 
NRXN1 
mutation 
Lower EBS in 
probands 
Higher EBS in 
probands Odds Ratio p-value 
in proband only 6 2 15 0.0513 
in both 3 2 7.5 0.1970 
in proband 9 4 11.25 0.0495 * 
in sibling only 1 5 NA NA 
One-sided Fisher’s exact test was performed with “in sibling only” group as control. *p-
value <0.05. 
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Supplementary data 
Supplementary data 4.1 Essentiality burden score of subjects from the Autism 
Sequencing Collection. 
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CHAPTER 5: Conclusion and future directions 
The goal of this dissertation is to systemically characterize human essential genes (EGs) 
and investigate the role of EGs in neurodevelopmental disorders such as ASD. From the 
analysis of the most comprehensive set of human EGs to date, this study demonstrated 
that i) EGs are not only relevant but also important for both Mendelian and complex 
diseases and ii) mutational load in EGs plays a significant role in the genetic basis of a 
neurodevelopmental disorder, ASD. Therefore, the analysis of EGs can serve as an 
important step for both interpretation and prioritization of ASD risk alleles, as well as a 
full understanding of the genetic landscapes of ASD and possibly more complex diseases. 
In light of the findings and discussions in previous chapters, I will discuss possible future 
directions for the analysis of EGs. 
Firstly, the extension of EG analysis to other complex diseases will further validate the 
key findings in this dissertation and lead to new insights into the role of the 
“essentialome” in human disease etiology. According to my results in Chapter 2, EGs are 
especially enriched among genes associated with early onset diseases, which is consistent 
with EGs’ vital role during embryonic development. Neurodevelopmental disorders (e.g. 
ASD, intellectual disabilities, developmental co-ordination disorder and attention-
deficit/hyperactivity disorder) are a group of conditions that manifest early in the 
development of children. Moreover, some neurodevelopmental disorders may share 
similar genetic risk factors (Smoller et al., 2013) and they frequently co-occur (Leitner, 
2014; Tonnsen et al., 2016). Therefore, neurodevelopmental disorders other than ASD 
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are plausible targets for future analyses of EGs. However, we cannot rule out the 
possibility that EGs could also play a role in later onset diseases, thus a comparison of the 
contributions of EGs in early onset and late onset diseases is warranted. 
Secondly, multiple lines of evidence suggest that genetic variants in functional elements 
within noncoding genomic regions play an important role in complex diseases (Zhang 
and Lupski, 2015). Since the coding regions of EGs are intolerant to deleterious 
mutations, it is expected that the regulatory elements of EGs may also have a distinct 
mutational spectrum. This notion is supported by Lek et al., who observed that the most 
highly mutational constrained genes (which overlap greatly with EGs) are depleted for 
expression quantitative loci (eQTL) (Lek et al., 2016). It implies that the regulatory 
elements of EGs are less redundant and functional variants in these elements are more 
likely to contribute to disease-related phenotypes. Therefore, a better understanding of 
the regulatory elements of EGs will improve our ability to interpret the functional 
consequences of non-coding variants discovered from whole genome sequencing studies. 
Moreover, by including variants in noncoding regulatory regions of EGs in the individual 
essentiality burden score (EBS), the power of EBS to predict individual ASD risk will 
likely be enhanced. In order to achieve this goal, one of the key problems to be solved is 
to credibly identify the regulatory elements for each EG. Multiple approaches can be 
applied independently or together to identify the regulatory elements of EGs. For 
example, analysis of eQTLs establishes the association between non-coding variants and 
gene expression levels by combining whole genome sequencing data and RNA 
sequencing data of the same individuals (Albert and Kruglyak, 2015). Chromosome 
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conformation capture followed by massively parallel sequencing (Hi-C) allows whole 
genome mapping of long range physical interactions (Lieberman-Aiden et al., 2009). 
With careful data quality control and selection of predictive models, eQTL and/or Hi-C 
data can be used to systematically assign regulatory elements to EGs. 
Last but not least, compiling a complete set of ~6,000 putative human EGs will be an 
achievable goal in the near future, as the genetic community including the International 
Mouse Phenotyping Consortium (IMPC) continues to produce and phenotype knockout 
mouse lines for the remainder of the ~20,000 genes in the mouse genome. Before this 
task is completed, an alternative approach to expand the current catalog of human EGs is 
to take advantage of essentiality in model organisms other than mouse. Large scale 
phenotypic analysis of mutant strains has been performed in S. cerevisiae (Giaever et al., 
2002; Winzeler et al., 1999), C. elegans  (Clark et al., 1988; Johnsen and Baillie, 1991), 
D. melanogaster (Boutros et al., 2004; Dietzl et al., 2007; Kamath et al., 2003) and D. 
rerio (zebrafish) (Amsterdam et al., 2004).  Human orthologs of EGs in these organisms 
are also plausible candidates for human EGs. However, since these organisms are not as 
close evolutionary relatives to human as mouse, EGs in these organisms may not be 
essential in mammals because of commonly occurring gene duplication during evolution 
(Holland et al., 1994). Therefore, extra care should be taken when inferring human EGs 
from these organisms. For example, human orthologs of EGs in multiple organisms could 
be highly conserved during evolution and thus are more likely to be EGs in human. 
Overall, a larger or eventually complete catalog of human EGs will further deepen our 
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understanding of basic biological processes and their contribution of EGs to human 
disease. 
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